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Antibiotic Tolerance and Heteroresistance: Associated Fitness Costs and
Potential in Evading Antibiotic Killing
Abstract
Streptococcus pneumoniae is a prominent human pathogen that causes both invasive and non-invasive
diseases, such as otitis media, pneumonia, meningitis, and bacteremia. Although it is frequently an
asymptomatic colonizer of the human nasopharynx, S. pneumoniae is a major cause of morbidity and
mortality in the immune compromised population, young children, and the elderly. Up until the 1970s, S.
pneumoniae was susceptible to almost all antibiotics. Since then, this pathogen has gained resistance to
a variety of antibiotic treatments, including beta-lactams, macrolides, and fluoroquinolones.
In the first chapter, we focused on fluoroquinolone resistance in S. pneumoniae. Fluoroquinolones are one
of the most frequently prescribed antibiotics, yet fluoroquinolone resistance in S. pneumoniae is still rare
compared to other antibiotics resistance, such as beta-lactams. In this study, we investigated the
mechanism(s) underlying this intriguing case by assessing the efficiency and fitness costs of horizontal
transfer of fluoroquinolone resistance determinants. We hypothesized that the fitness tradeoffs incurred
by resistance determinants would define the likelihood of such resistance to emerge in a clinical setting.
Clinically relevant fluoroquinolone resistance requires both on-target mutations in topoisomerase IV parC
and DNA gyrase gyrA. The wild-type S. pneumoniae TIGR4 was not readily transformed with single
mutations in gyrA or parC; however, it was readily transformed with double on-target mutations in gyrA
and parC. Compared to the wild type, the single on-target mutants were attenuated, whereas the double
on-target mutant was virulent. This suggests that clinically relevant, high-level fluoroquinolone resistance
requires the combination of several on-target mutations, which could be acquired via horizontal transfer.
The combination of the extremely low probability of acquiring two or more mutations simultaneously
from different target genes and the deleterious fitness tradeoffs imposed by individual on-target
mutations in gyrA or parC likely result in the infrequent prevalence of fluoroquinolone resistance in S.
pneumoniae. Through in vitro serial passaging, we identified a novel mutation (N291D) in the efflux pump
patA that facilitated the acquisition of the on-target mutations in parC and gyrA via horizontal transfer
with minimal fitness tradeoffs. We also modeled the evolution of fluoroquinolone resistance in a murine
host and identified mutation(s) that arose and fixated during in vivo passaging. Interestingly, the
experimentally-evolved isolates from the in vivo passaging study did not encode on-target mutations for
fluoroquinolone resistance and instead displayed tolerance, which potentially facilitated the subsequent
acquisition of fluoroquinolone resistance.
In the next chapter, we investigated how fitness tradeoffs and horizontal transfer play a role in the
emergence and spread of another mainstay of treatment of pneumococcal infection, beta-lactamsspecifically, penicillin, which inhibit wall synthesis. We found that recombination with related viridans
species via horizontal transfer may be preferable to de novo on-target mutations in penicillin-binding
proteins in S. pneumoniae to acquire resistance more rapidly without initially losing in vivo fitness. Initial
recombinants retained virulence in vivo and could readily acquire higher resistance via subsequent
transformation. The final recombinants displayed tolerance to penicillin, having reduced kill kinetics
compared to the wild type. This suggests that S. pneumoniae might have minimized fitness tradeoffs by
developing tolerance via horizonal transfer with related viridans group streptococci, which would serve as
a stepping stone for subsequent development of resistance.
In the next study, we explored an underlying mechanism of antibiotic tolerance in S. pneumoniae. In our
model of the evolution of antibiotic resistance, rny that encodes ribonuclease Y (RNAse Y) was a
mutational hotspot across multiple antibiotics. The rny knockout mutant was fully virulent, indicating that
deletion of this gene imposed minimal to no fitness tradeoffs. Disruptions in RNA degradation resulted in
tolerance to several classes of antibiotics and reduced antibiotic treatment efficacy in vivo.

In the final chapter, we investigated whether other phenomena that allow bacteria to withstand antibiotic
killing, such as heteroresistance, can affect antibiotic treatment outcomes clinically. We found that
vancomycin heteroresistance is associated with treatment failure and poor outcomes in coagulasenegative staphylococci (CoNS) from pediatric leukemia patients.
Taken together, this dissertation provides insights into strategies of S. pneumoniae for striking a balance
between maximizing resistance potential while minimizing fitness tradeoffs, thereby potentially
contributing to the development of more-effective antibiotics for treatment of pneumococcal disease. It
also provided insights into the association between heteroresistance in CoNS and clinical outcomes.
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ABSTRACT

Streptococcus pneumoniae is a prominent human pathogen that causes both
invasive and non-invasive diseases, such as otitis media, pneumonia, meningitis, and
bacteremia. Although it is frequently an asymptomatic colonizer of the human
nasopharynx, S. pneumoniae is a major cause of morbidity and mortality in the immune
compromised population, young children, and the elderly. Up until the 1970s, S.
pneumoniae was susceptible to almost all antibiotics. Since then, this pathogen has
gained resistance to a variety of antibiotic treatments, including beta-lactams, macrolides,
and fluoroquinolones.
In the first chapter, we focused on fluoroquinolone resistance in S. pneumoniae.
Fluoroquinolones are one of the most frequently prescribed antibiotics, yet
fluoroquinolone resistance in S. pneumoniae is still rare compared to other antibiotics
resistance, such as beta-lactams. In this study, we investigated the mechanism(s)
underlying this intriguing case by assessing the efficiency and fitness costs of horizontal
transfer of fluoroquinolone resistance determinants. We hypothesized that the fitness
tradeoffs incurred by resistance determinants would define the likelihood of such
resistance to emerge in a clinical setting. Clinically relevant fluoroquinolone resistance
requires both on-target mutations in topoisomerase IV parC and DNA gyrase gyrA. The
wild-type S. pneumoniae TIGR4 was not readily transformed with single mutations in
gyrA or parC; however, it was readily transformed with double on-target mutations in
gyrA and parC. Compared to the wild type, the single on-target mutants were attenuated,
whereas the double on-target mutant was virulent. This suggests that clinically relevant,
high-level fluoroquinolone resistance requires the combination of several on-target
mutations, which could be acquired via horizontal transfer. The combination of the
extremely low probability of acquiring two or more mutations simultaneously from
different target genes and the deleterious fitness tradeoffs imposed by individual ontarget mutations in gyrA or parC likely result in the infrequent prevalence of
fluoroquinolone resistance in S. pneumoniae. Through in vitro serial passaging, we
identified a novel mutation (N291D) in the efflux pump patA that facilitated the
acquisition of the on-target mutations in parC and gyrA via horizontal transfer with
minimal fitness tradeoffs. We also modeled the evolution of fluoroquinolone resistance in
a murine host and identified mutation(s) that arose and fixated during in vivo passaging.
Interestingly, the experimentally-evolved isolates from the in vivo passaging study did
not encode on-target mutations for fluoroquinolone resistance and instead displayed
tolerance, which potentially facilitated the subsequent acquisition of fluoroquinolone
resistance.
In the next chapter, we investigated how fitness tradeoffs and horizontal transfer
play a role in the emergence and spread of another mainstay of treatment of
pneumococcal infection, beta-lactams- specifically, penicillin, which inhibit wall
synthesis. We found that recombination with related viridans species via horizontal
transfer may be preferable to de novo on-target mutations in penicillin-binding proteins in
S. pneumoniae to acquire resistance more rapidly without initially losing in vivo fitness.
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Initial recombinants retained virulence in vivo and could readily acquire higher resistance
via subsequent transformation. The final recombinants displayed tolerance to penicillin,
having reduced kill kinetics compared to the wild type. This suggests that S. pneumoniae
might have minimized fitness tradeoffs by developing tolerance via horizonal transfer
with related viridans group streptococci, which would serve as a stepping stone for
subsequent development of resistance.
In the next study, we explored an underlying mechanism of antibiotic tolerance in
S. pneumoniae. In our model of the evolution of antibiotic resistance, rny that encodes
ribonuclease Y (RNAse Y) was a mutational hotspot across multiple antibiotics. The rny
knockout mutant was fully virulent, indicating that deletion of this gene imposed minimal
to no fitness tradeoffs. Disruptions in RNA degradation resulted in tolerance to several
classes of antibiotics and reduced antibiotic treatment efficacy in vivo.
In the final chapter, we investigated whether other phenomena that allow bacteria
to withstand antibiotic killing, such as heteroresistance, can affect antibiotic treatment
outcomes clinically. We found that vancomycin heteroresistance is associated with
treatment failure and poor outcomes in coagulase-negative staphylococci (CoNS) from
pediatric leukemia patients.
Taken together, this dissertation provides insights into strategies of S. pneumoniae
for striking a balance between maximizing resistance potential while minimizing fitness
tradeoffs, thereby potentially contributing to the development of more-effective
antibiotics for treatment of pneumococcal disease. It also provided insights into the
association between heteroresistance in CoNS and clinical outcomes.
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CHAPTER 1.

INTRODUCTION

Streptococcus pneumoniae Epidemiology
Streptococcus pneumoniae was first identified in 1881 and recognized as the
causative agent of lobar pneumoniae in the late 1880s [1, 2]. It is a major human
pathogen, especially in the pediatric (children under 2 years), geriatric, and
immunocompromised populations worldwide (>65 years) [3]. Other high-risk groups
include those with chronic lung, disease, diabetes, asthma, smoking, alcohol abuse, solid
or hematologic malignancies, and sickle cell disease [4]. Although S. pneumoniae is
usually an asymptomatic member of the nasopharynx microbiota, it has the remarkable
ability to invade different human organs, causing mild to severe infection, such as otitis
media, pneumonia, meningitis, bacteremia, and sepsis [5].

S. pneumoniae Microbiology
S. pneumoniae is a non-motile, alpha-hemolytic, Gram-positive encapsulated
bacterium. The bacteria appear as lancet-shaped diplococci and are identified in the
laboratory by their sensitivity to optochin and bile-mediated lysis (deoxycholate) [6]. The
whole genome of S. pneumoniae TIGR4 (serotype 4) from a patient with meningitis was
sequenced and released by the Institute for Genetic Research in 1997. Since then, other
clinical strains have also been sequenced. Significant genetic diversity (up to 20%) in
DNA composition among clinical strains have been observed [7, 8]. Whole genome
sequence analysis indicates that S. pneumoniae lacks genes required for a complete
tricarboxylic acid cycle and the respiratory electron transport chain [9]. Instead, S.
pneumoniae generates energy from fermentation and metabolism of a wide range of
carbohydrates and glycans [10]. This ability enables the bacteria to adapt and survive in
different host niches that contain distinct prevailing carbohydrates.

Transformation
Naturally competent for genetic transformation, S. pneumoniae can uptake and
recombine exogeneous DNA into its genome for genetic variability and advantageous
traits. Horizontal transfer via transformation is a main driver of adaptation and antibiotic
resistance in this species. This phenomenon of transformation was first studied in vivo by
Frederick Griffith [11], fueling the discovery of DNA as the hereditary material [12].
Transformation in S. pneumoniae is activated by a competence stimulating peptide
(CSP), which is a pheromone that competent bacterial cells produce to initiate the uptake
and homologous recombination of exogenous DNA. S. pneumoniae utilizes this
transformation machinery to acquire antibiotic resistance determinants and other
advantageous genes from within species and closely related species coinhabiting similar
host niches, such as S. mitis and S. oralis [13-15]. For example, it has been shown that S.
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pneumoniae and S. mitis exchange distinct fluoroquinolone or beta-lactams resistanceconferring regions in penicillin-binding proteins and DNA gyrase [16-18].

Current Antibiotic Treatment for Pneumococcal Infection
For mild cases of pneumococcal infection in which oral antibiotics are warranted,
amoxicillin, second- or third-generation cephalosporins, or oral levofloxacin, if the strain
is susceptible, are recommended [19]. For mild to moderate pediatric pneumococcal
pneumonia caused by penicillin-sensitive strains, amoxicillin is the first-line therapy.
Alternatives include third-generation cephalosporins, including ceftriaxone or
cefotaxime, for patient populations with widespread penicillin resistance. For
community-acquired pneumonia in adults, amoxicillin, which is still a drug of choice if
the strain is susceptible, macrolides (azithromycin, erythromycin, or clarithromycin), or a
respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) are
recommended for mild cases; in severe cases, requiring hospitalization, ceftriaxone or
cefotaxime are first line agents, followed by vancomycin for life threatening infection
[20]. To treat pneumococcal meningitis caused by susceptible strains, ceftriaxone is the
first line of therapy. In intermediate to resistant cases, high dose ceftriaxone or
cefotaxime is supplemented with vancomycin.

Antibiotic Resistance in S. pneumoniae
For decades, common clinically used antibiotics such as beta- lactams,
macrolides, and fluoroquinolones have been the standard treatment for pneumococcal
infections. However, there has been a worldwide increase in the number of cases of S.
pneumoniae resistant to multiple classes of antibiotics, including fluoroquinolones
(levofloxacin, ciprofloxacin, and gemifloxacin), folate inhibitors (trimethoprim and
sulfamethoxazole), cell-wall synthesis inhibitors (penicillin), and protein synthesis
inhibitors (azithromycin, doxycycline, tetracycline, and minocycline [21]. According to
the CDC, in 2019, 30% of about 30,000 cases of invasive pneumococcal diseases resulted
from S. pneumoniae that was resistant to at least one antibiotic [22]. In the United States,
approximately 20% to 40% of pneumococcal isolates are resistant to macrolides [21, 23];
approximately 1.4% and 2% are intermediate and resistant to beta-lactams, respectively
[24]; and only 1% to 2% are resistant to fluoroquinolones. Antibiotic resistance has
complicated treatment for pneumococcal infections and often results in treatment failure
in cases that otherwise would have been effectively treated with commonly used
antibiotics [25, 26]. The rapid emergence of antibacterial resistance poses a major threat
to global public health by rendering standard treatments for pneumococcal infection less
effective and more costly.
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Beta-Lactams Resistance
Over the past few decades, beta-lactams (such as penicillins, cephalosporins, and
carbapenems) have been the first-line treatment of pneumococcal infection. However,
global widespread resistance to beta-lactams have complicated pneumococcal infection
treatment since the late 1970s [27, 28]. Beta-lactam antibiotics induce bacterial lysis and
loss of viability by binding to penicillin-binding proteins, thereby inhibiting cell wall
synthesis [29]. Resistance of S. pneumoniae to beta-lactams occurs when alterations in
the penicillin-binding proteins reduce their binding affinity to the antibiotics [30, 31].
Beta-lactam resistance in S. pneumoniae is most often conferred by mosaic variants of the
target enzymes—penicillin-binding proteins. The mosaic variants often result from
homologous recombination during horizontal transfer within species and/or from related
oral streptococcal species, such as S. mitis and S. oralis [32].

Fluoroquinolone Resistance
Unlike the widespread beta-lactam resistance, fluoroquinolone (FQ) resistance in
S. pneumoniae is still very low. Only 1 to 2% of pneumococcal isolates in the United
States are resistant to fluoroquinolones [33, 34]. The highest prevalence of
fluoroquinolone resistance (4-13%) was reported in Croatia and Hong Kong [35, 36].
Fluoroquinolones (such as ciprofloxacin, levofloxacin, and moxifloxacin) inhibit
topoisomerase IV (ParC and ParE) and gyrAse (GyrA), which are responsible for
unwinding supercoiled DNA, thereby halting DNA replication and causing cell death
[37]. Mutations in the on-target genes parC and/or gyrA confer resistance to
fluoroquinolone resistance in S. pneumoniae. Acquisition of fluoroquinolone resistance
occurs in a stepwise fashion thru acquisition of antibiotic resistance determinants or thru
adaptation via selection of beneficial de novo mutations [38]. It is quite concerning that
clinical isolates classified as susceptible might have already harbored single point
mutations in either parC or gyrA, which could acquire subsequent mutations to gain highlevel resistance and disseminate.

On-Target versus Off-Target Mutations
There are multiple pathways underlying resistance against an antibiotic.
Antibiotic resistance mutations can be classified into two categories: on-target and offtarget mutations. Off-target mutations are mutations that occur outside of the primary
target(s) of the antibiotic. They are not the direct or intended target(s) of a particular
antibiotic but can confer some level of resistance. During an antibiotic exposure, bacteria
can activate pathways that are not directly targeted by that antibiotic to survive. Such
pathways include stress response, metabolic regulation, transcriptional regulation, efflux /
influx regulation, and genes involved in metabolism, transport, and regulation of gene
expression [39-41]. For example, fluoroquinolones, such as ciprofloxacin and
levofloxacin, inhibit gyrase A and topoisomerase IV activities. Mutations in the genes
encoding gyrase A or topoisomerase IV are considered the on-target mutations for
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fluoroquinolone resistance, whereas mutations in an efflux pump (for example, patA) are
considered off-target mutations.

Antibiotic Tolerance and Heteroresistance
Often overshadowed by the prominent phenomenon of antibiotic resistance,
tolerance and heteroresistance are among the highly possible culprits of unexplained
antibiotic treatment failure and recalcitrant infections [42, 43]. Tolerance refers to the
ability of the bacteria to withstand the lethal actions of bactericidal antibiotics without
significant increases in the minimum inhibitory concentration (MIC) [44]. While
antibiotic resistance is readily detected by traditional clinical MIC assays and thus has
been extensively studied and characterized, tolerance and heteroresistance are often
overlooked and undetected. Currently, there is no gold standard for identifying antibiotic
tolerant strains. Although antibiotic kill kinetics (or time-kill curves) have been
conducted to detect antibiotic tolerance, those assays are often laborious and challenging
[45]. Despite these obstacles, antibiotic tolerance has been reported in both Gramnegative and Gram-positive bacteria and served as a potential avenue for the subsequent
development of high-level resistance.
Heteroresistance has also been reported in multiple pathogens- such as S. aureus,
Acinetobacter baumanii, Pseudomonas aeruginosa- against a variety classes of
antibiotics, such as beta-lactams, vancomycin, aminoglycosides [46, 47]. Heteroresistance is a phenomenon when the majority of the population is susceptible to an
antibiotic, while a small proportion of bacterial cells demonstrates resistance to that
antibiotic [43]. The resistant subpopulation occurs at a very low frequency, about 1 in 105
cells. They are often undetected by clinical testing and usually misclassified as
susceptible. In contrast, persistence describes a population in which a small subpopulation (from 0.001% to 1%) is tolerant to an antibiotic [48, 49]. Similar to tolerance,
there is no standardized clinical testing method to detect heteroresistance or persistence.
The gold standard method to detect heteroresistance is population analysis profile [50];
however, it is extremely laborious and thus not feasible for clinical use. The presence of
the resistant subpopulation contributes to reduced efficacy of antibiotics as these bacteria
are not effectively eradicated and can potentially expand upon subsequent antibiotic
exposure [43, 51, 52]. Emergence of heteroresistance also poses a significant threat to the
healthcare community since it potentially precedes antibiotic resistance [53].

Fitness Tradeoff
Bacterial fitness refers to the ability of the bacteria to adapt and thrive in an
environment. Antibiotic resistance conferred by on- and/or off-target mutation(s) is often
accompanied with fitness costs [54, 55]. While those mutations enable the bacteria to
survive under antibiotic pressure, they often render the target enzymes suboptimal in the
absence of antibiotics. Therefore, those mutations can reduce bacterial fitness, which
manifests as reduced growth rates, virulence, and colonization. Mutations that impart
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little to no compromise in fitness costs to the bacteria have a higher chance of surviving
and persisting in the population [54, 56].

Hypothesis and Objectives
In this study, we investigated the impact of fitness tradeoffs on the spread and
emergence of antibiotic resistance in S. pneumoniae. In chapters 2, 3 and 4, we tested our
hypothesis that the emergence and spread of fluoroquinolones and beta-lactams resistance
determinants via horizontal transfer depends on the extent of fitness costs associated with
those determinants. To survive and disseminate, resistant bacteria must strike a balance
between maximizing resistance potential and preserving fitness. We also studied other
phenomena that contribute to the emergence and spread of antibiotic resistance in S.
pneumoniae and treatment failure. In chapter 6, we studied tolerance in S. pneumoniae
based on our hypothesis that tolerance likely occurs as a stepping stone to the
development of antibiotic resistance to circumvent high fitness costs of on-target
mutations. Finally, in chapter 5, we investigated whether vancomycin heteroresistance is
associated with poor clinical outcomes in bloodstream infections caused by coagulasenegative staphylococci.
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CHAPTER 2. FITNESS CONSTRAINTS HINDER HORIZONTAL TRANSFER
OF FLUOROQUINOLINE RESISTANCE DETERMINANTS IN
STREPTOCOCCUS PNEUMONIAE

Introduction
S. pneumoniae is a major cause of morbidity and mortality particularly in young
children and elderly populations [3]. Annually, about half a million deaths among
children younger than the age of 5, the immunocompromised, and the elderly result from
pneumococcal disease worldwide [57]. Although S. pneumoniae usually colonizes the
upper respiratory tract asymptomatically, it can become pathogenic especially when host
defenses are weakened or compromised, causing mild to invasive diseases, such as
sinusitis, acute otitis media, pneumonia, bacteremia, and meningitis [3, 5]. For decades,
common clinically used antibiotics such as beta-lactams, macrolides, and fluoroquinolones have been the standard treatment for pneumococcal infections [58]. Antibiotic
resistance has complicated treatment for pneumococcal infections and often results in
treatment failure in cases that otherwise would have been effectively treated with
commonly used antibiotics. There has been a worldwide increase in the number of cases
of S. pneumoniae resistant to multiple classes of antibiotics, including fluoroquinolones
(levofloxacin, ciprofloxacin, and gemifloxacin), folate inhibitors (trimethoprim and
sulfamethoxazole), cell-wall synthesis inhibitors (penicillin), and protein synthesis
inhibitors (azithromycin, doxycycline, tetracycline, and minocycline) [21]. According to
the CDC, in 2015, 30% of about 30,000 cases of invasive pneumococcal disease resulted
from S. pneumoniae that was resistant to more than one antibiotic [24]. In the United
States, approximately 20% to 40% of pneumococcal isolates are resistant to macrolides
[22, 23] and 13% to 30% are resistant to beta-lactams [23, 59-61]. Unlike macrolide and
beta-lactam resistance, there have been paradoxical observations in the case of
fluoroquinolone resistance. Globally, fluoroquinolones are one of the most frequently
prescribed antibiotics [33]. Despite a high usage rate, only limited cases of highly
fluoroquinolone-resistant pneumococcal isolates have been reported [25, 26]. The
prevalence of fluoroquinolone resistance remains low regardless of the frequent usage of
fluoroquinolone in Asia and Europe, Spain, ranging from 0.6% to 9.8% (Table 2-1). In
North America, surveillance studies showed that fluoroquinolone resistance is still
uncommon, approximately <2% (Table 2-1).
Ciprofloxacin was the first fluoroquinolone prescribed to treat lower respiratory
tract infections [62]. Currently, ciprofloxacin is not the first-line treatment for
pneumococcal infection due to its limited potency against S. pneumoniae and potential
for rapid emergence of resistance [35, 63-66]. A newer fluoroquinolone, levofloxacin,
which has greater potency against S. pneumoniae, is one of the current standard
treatments for community-acquired pneumococcal pneumoniae [67]. Acquisition of
levofloxacin resistance in S. pneumoniae has been reported to occur rapidly during
antibiotic therapy [68]. High-level fluoroquinolone resistance requires alterations in the
quinolone resistance-determining regions in the on-target genes, topoisomerase IV (parC)
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Table 2-1.

Prevalence of fluoroquinolone resistance from 1988 to 2015

Fluoroquinolone Usage
(Prescriptions per 1000
Persons)
37.5
Not available
Ciprofloxacin
38.2 to 59.4
Respiratory
fluoroquinolone
5.3 to 27.4
Not available
Not available
Not available
39 to 106
Not available
Not available
Not available
Not available

Fluoroquinolone Prevalence

Periods

Region

1.2% isolates first step mutation in parC
6.7% efflux phenotype
0.2% resistant to levofloxacin
1.8% resistant to ciprofloxacin

2002-2006

2004-2005 to 2014-2015 Germany
1988-2006
Canada

[70]
[25, 71, 72]

1.2% non-susceptible to levofloxacin
1.1% non-susceptible to moxifloxacin

1988-2006

Canada

[25, 71, 72]

0% in 1993 to 1.7% in 1997 and 1998
1.5%
2.9%
<2% resistant to levofloxacin
< 2% resistant to levofloxacin
< 1% resistant to moxifloxacin
4-13% resistant to fluoroquinolones
(ciprofloxacin)
4% resistant to newer fluoroquinolones
(levofloxacin, moxifloxacin)
7.1%
1.64 % resistant to ciprofloxacin, 0% to
other fluoroquinolones

1988 to 1997
1993 to 1994
1997 to 1998
2007-2016
1995-2002
2008
2000

Canada
Canada

[64]
[69]

Canada
USA

[25, 73]
[33, 34]
[36]

2009 to 2010

Croatia and
Hong Kong
Asia

1998-1999
2000-2002

Spain
Hungary

[75]
[76]
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Germany

Ref

[69]

[74]

and/or DNA gyrase (gyrA), that decrease the drug binding affinity of the target enzymes
[77]. Both topoisomerase IV and DNA gyrase are responsible for relieving chromosomal
supercoiling and DNA torsion during DNA replication and transcription [78].
Topoisomerase IV relaxes positive supercoiling and decatenates interlocked daughter
chromosomes to complete DNA replication [79]. Complementary to the role of
topoisomerase IV, DNA gyrase induces negative supercoiling or relaxes positive
supercoils.
In addition to the high usage rate of fluoroquinolones, S. pneumoniae is naturally
competent. The bacteria can naturally transform and acquire resistance determinants via
horizontal transfer [80]. The emergence and spread of fluoroquinolone resistance in S.
pneumoniae result from de novo mutations or horizontal transfer of resistance
determinants [38]. Horizontal transfer can accelerate the spread of antibiotic resistance at
a more rapid rate than de novo mutations, which occur at very low frequencies (10-8 to
10-7 per generation) [81]. However, fluoroquinolone resistance is still extremely low, and
the reason underlying the low prevalence of fluoroquinolone resistance remains
unknown. We hypothesized that there may be barriers to acquiring fluoroquinoloneresistant mutations and/or to fixating those mutations in the population. One such barrier
could be high fitness costs associated with those mutations. In the absence of antibiotics,
mutations with high fitness costs would diminish the ability of the bacteria to survive and
replicate in the host, where the bacteria are under selective pressure from the immune
system [55]. In this paper, we demonstrated that horizontal transfer of on-target
fluoroquinolone resistance determinants imposed deleterious fitness costs in S.
pneumoniae and that high-level fluoroquinolone resistance required a specific
combination of on-target mutations. The high fitness costs associated with the on-target
fluoroquinolone resistance determinants and the requirement for a select combination of
mutations likely contribute to the paucity of fluoroquinolone-resistant strains of S.
pneumoniae worldwide despite continued high-level fluroquinolone usage clinically.

Methods

Media and growth conditions
For this study, S. pneumoniae was either grown in C+Y, a chemically-defined
semi-synthetic casein liquid media supplemented with 0.5% yeast extract, ThyB media
(Todd Hewitt Broth + 0.2% yeast extract from Sigma Aldrich), or on blood agar plates
containing tryptic soy agar (EMD Chemicals, New Jersey) and 3% defibrinated sheep
blood. Cultures of S. pneumoniae were inoculated from overnight streaked blood agar
plates and then incubated at 37oC in 5% CO2. In addition to the respective
fluoroquinolone for selection of transformants, all blood agar plates were supplemented
with neomycin at 20 µg/mL to select for S. pneumoniae. S. pneumoniae is naturally
resistant to neomycin. Strains used in this study and their respective ciprofloxacin and
levofloxacin MICs (µg/mL) are listed in Table 2-2.
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Table 2-2.

Strains used in this study and respective MICs
MIC (µg/mL)
Ciprofloxacin
Levofloxacin
4
1

Strains
TIGR4

Description
TIGR4 wild type,
serotype 4

CDC001

Serotype 9V

4

1

D39

D39 wild type,
serotype 2

4

1

Tn-seq mutant TIGR4
library

4

1

Generated by
Amy Iverson
This study

S79Y parC

Single point
mutation S79Y in
topoisomerase IV
parC

8

2

This study

S81F gyrA

Single point
mutation S81F in
gyrAse A gyrA

8

2

This study

S79Y parC &
S81F gyrA

Double point
mutations S79Y
in parC and S81F
in gyrA

16

4

This study

S79Y parC &
D435N gyrB

Double point
mutations S79Y
in parC and
D435N in gyrB

8

2

This study

9

Source
www.tigr.org

CDC

MIC determination via E-tests
The wild-type TIGR4, single point mutants S79Y parC and S81F gyrA, and
double mutants S79Y parC & S81F gyrA and S79Y parC & D435N gyrB strains were
grown on blood agar plates overnight, inoculated into ThyB, and incubated 37oC with 5%
CO2 until reaching mid-logarithmic phase at OD620 ~0.4. Then, 100 µL of the bacterial
culture were spread onto blood agar plates. A levofloxacin E-test strip (bioMerieux) was
added onto the center of each plate. Minimum inhibitory concentration MIC (µg/mL) was
determined to be the concentration at which the symmetrical inhibition ellipse edge
intersects the E-test strips on the plate [82].

Genomic DNA extraction
To extract genomic DNA for transformation and whole genome sequencing in
this study, the aqueous / organic extraction method using phenol chloroform was
performed. TIGR4 and mutant strains were grown in ThyB to late logarithmic phase at
OD620 ~0.6 and pelleted at 6000 x g for 10 minutes followed by resuspension in 1 mL
1x PBS containing 50 µL 10% DOC, 50 µl 10% SDS, and 10 µL of 10mg/mL Proteinase
K (Sigma). The mixture was incubated for lysis until clear (approximately 5 minutes) at
37oC, mixed with 500 µL phenol:chloroform:isoamyl alcohol (Sigma), transferred to
phase-lock tubes (Quantabio), and centrifuged at maximum speed for the separation of
aqueous and organic phases. Then 500 µL chloroform: isoamyl alcohol was mixed with
the aqueous phase and centrifuged as above. For DNA precipitation, the aqueous phase
was transferred to a new Eppendorf tube containing 100% ethanol. Precipitated DNA was
washed with ice cold 70% ethanol, pelleted, dried, and resuspended in nuclease-free
water.

Transformation
Cultures of S. pneumoniae were inoculated in C+Y media and incubated at 37oC
with 5% CO2 until OD620~0.07 to 0.1. Then, 5 µg of gDNA and 3 µL of CSP2 were added
to 1 mL of the bacterial cultures. Three different types of DNA were used for
transformation experiments: 2 kb PCR fragments encoding select point mutations,
genomic DNA of fluoroquinolone resistant S. pneumoniae, or genomic DNA of S.
viridans clinical isolates. The genomic DNA from both species was extracted using the
aqueous / organic extraction protocol as described previously. After addition of DNA and
CSP, the cultures were incubated for 3 hours at 37oC with 5% CO2, followed by plating
of 100 µL of the transformation mixture 5 blood agar plates containing select antibiotics.
Colony-forming units (CFUs/mL) were enumerated at 24 and/or 48 hours of incubation.
Transformation efficiency was calculated as the ratio of transformant colonies
(CFUs/mL) on select antibiotic plates to the total number of colonies (CFUs/mL) on
blood plates without the antibiotic.
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In vitro passaging
TIGR4 was diluted 1:100 fresh ThyB containing increasing subinhibitory
concentrations of either ciprofloxacin or levofloxacin and incubated until reaching
exponential phase (OD620~0.6). Then bacteria stocks in glycerol were stored at -80oC
before serving as an inoculum for the next passage. Each subsequent passage contained
progressively increasing 2-fold dilutions of the respective antibiotic. The passaging
continued for 30 days. Bacterial culture of the last passage at the highest concentration of
ciprofloxacin or levofloxacin was spread on blood agar plates, and three colonies were
selected for identification of mutations that arose at the end of passaging with either
levofloxacin or ciprofloxacin via whole genome sequencing.

Mouse experiments
To determine the virulence of the mutants in terms of fitness costs in vivo, 6week-old female BALB/c mice (Jackson laboratory) were intranasally infected with the
wild-type TIGR4 or the mutant strains (106 CFUs in 100 µL). At 24 hours post challenge,
2 µL of nasal samples and 5 µL of blood samples were collected via nasal lavage and tail
bleeding, respectively. The nasal and blood samples were then serially diluted and
spotted on blood agar plates for enumeration of bacterial burden. Plates were incubated
overnight at 37oC and 5% CO2. Mice were closely monitored for disease progression for
10 days and euthanized via CO2 asphyxiation. Bacterial titers (CFUs/mL) were compared
using non-parametric Mann-Whitney t-test in Prism 7.

Ethics statement
All experiments involving animals were performed with prior approval of and in
accordance with guidelines of the St. Jude Institutional Animal Care and Use Committee.
The St. Jude laboratory animal facilities are fully accredited by the American Association
for Accreditation of Laboratory Animal Care. Laboratory animals are maintained in
accordance with the applicable portions of the Animal Welfare Act and the guidelines
prescribed in Guide for the Care and Use of Laboratory Animals.

RNA extraction, rRNA depletion, and RNA-Seq
Wild-type TIGR4, S79Y parC, S81F gyrA, and double mutants S79Y parC &
S81F gyrA, and S79Y parC & D435N gyrB were grown in C+Y until mid-exponential
phase (OD620 ~0.4) and pelleted via centrifugation at 6,000 x g for 10 minutes. The
supernatant was discarded, and RNA was extracted from the pellets using the Qiagen
RNeasy kit. Extra DNA removal steps were conducted to eliminate DNA from the RNA
samples, following the protocol from DNase Inactivation Reagent from DNA Free DNA
removal kit (Thermo AM1906). To remove rRNA from the extracted RNA samples,
rRNA depletion was conducted based on the protocol developed by Culviner et al. [83].
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Library preparation for RNA sequencing was completed following the protocol of
NEBNext Ultra II RNA Library Prep kit for Illumina (E7770, E7775).

In vivo passaging
To model the evolution of fluoroquinolone resistance in vivo, three groups of 7week-old immunocompetent BALB/c mice were intranasally infected with 100 µL
containing 106 CFUs of TIGR4. Six hours post-infection, mice were administered a
sublethal dose of levofloxacin intraperitoneally. The initial dosage of levofloxacin (25
mg/kg) was utilized as it eliminated 90% to 99% of the bacterial population (data not
shown). After 15 passages, the levofloxacin dosage was doubled in each subsequent
passage. For each passage, twelve hours after levofloxacin treatment, bacteria were
collected from lungs of infected mice via dissection. The lungs were homogenized, then
bacteria in lung homogenates were collected via centrifugation at 300 x g for 5 minutes,
plated on blood agar plates and grown at 37oC with 5% CO2. for 12 hours, collected from
the agar plates, and frozen in aliquots containing glycerol. Frozen aliquots from each
passage served as the inoculum to infect the next group of mice for the subsequent,
respective lineage, and the remaining aliquots were used for genomic DNA extraction.

Whole genome sequencing
Genomic DNA samples were sent to Hartwell Center for Bioinformatics and
Biotechnolgy whole genome sequencing. Sequence libraries were prepared according to
Illumina HiSeq protocol. The reads were assembled in Breseq and compared to the
TIGR4 reference genome (AE005672.3) for identification of mutations resulting from
recombination events and de novo point mutations.

Antibiotic kill curves
The wild-type TIGR4, single- and double-point mutants were grown in ThyB to
early-exponential phase OD620 ~0.2. The bacteria were exposed to progressively
increasing concentrations of ciprofloxacin, levofloxacin, and moxifloxacin, ranging from
1x to 4x MIC of the wild type. Before and after antibiotic exposure, bacterial CFUs were
serially diluted and spotted onto blood agar plates. Plates were incubated overnight at
37oC with 5% CO2.

H2O2 production measurement
The evolved isolates and TIGR4 were grown for 7 hours in ThyB until midexponential phase (OD620 ~0.4), centrifuged, and resuspended in 1x PBS. Bacterial
supernatant was collected for the Amplex Red Hydrogen Peroxide/Peroxidase assay
(ThermoFisher Scientific A22188), then 50 µL Amplex Red reagent was added to 50 µL
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of the supernatant in each microplate well. The absorbance value (OD562) was measured
by using a BioTek plate reader. Amount of H2O2 of each strain was calculated and
normalized to its amount of total cellular protein, which was determined via a
bicinchonicic acid (BCA) protein assay.

Results

Fluoroquinolone resistance in S. pneumoniae did not occur readily via de novo
mutations
Although the prevalence of fluoroquinolone resistance remains relatively low
compared to other antibiotics, it still occurs clinically (Table 2-1). Cases of levofloxacin
resistance in S. pneumoniae arising during therapy and resultant treatment failure have
been reported [68]. Thus, we aimed to gain insights into the emergence and spread of
fluoroquinolone resistance by modeling the evolution of fluoroquinolone resistance and
identifying mutations favored by fluoroquinolone pressure and/or the host’s immune
response. First, we attempted to identify mutations that arose under antibiotic pressure
solely via in vitro passaging with either ciprofloxacin or levofloxacin. After 30 passages,
TIGR4 did not develop significant resistance to ciprofloxacin as it only became resistant
to 8 µg/mL (2x MIC) (Figure 2-1A), which is markedly lower than clinically relevant
MICs. Levofloxacin resistance was not observed after an extensive period of in vitro
passaging (Figure 2-1B). Three independent colonies isolated from the in vitro passaging
population under ciprofloxacin pressure were sequenced. Whole genome sequencing data
demonstrated that those three colonies encode double point mutations in the on-target
genes parC and gyrA, D83N and S81F, respectively. The in vitro passaging isolates under
levofloxacin pressure were not sequenced because an MIC higher than that of TIGR4 was
not reached. The TIGR4 strain developed slight resistance to ciprofloxacin as a result of
double mutations in the on-target enzymes.
We also modeled the evolution of fluoroquinolone resistance under the host’s
immune response. To search for mutations associated with fluoroquinolone resistance in
vivo, we developed a murine challenge model for studying the evolution of
fluoroquinolone resistance under both levofloxacin and immune pressure (Figure 2-2A).
The wild-type TIGR4 underwent 30 passages in three independent lineages of
immunocompetent BALB/c mice under increasing levofloxacin pressure (Figure 2-2B).
Whole genome sequencing analysis of each experimentally-evolved isolate collected
from the final passage indicated the absence of on-target mutations in either gyrA or
parC. We measured the levofloxacin MIC of each isolate using E-tests. Surprisingly,
MICs of the isolates (1.5 µg/mL) were relatively similar to that of the parental, wild-type
strain (1 µg/mL) (Table 2-3). No marked change in levofloxacin MIC observed in the
experimentally-evolved isolate suggests that the isolates did not become resistant to the
antibiotic.
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Figure 2-1. S. pneumoniae demonstrated de novo resistance in vitro, while
developed tolerance in vivo
A and B) in vitro passaging. S. pneumoniae was exposed to gradually increasing
concentrations of both ciprofloxacin and levofloxacin, respectively for 30 days.
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Figure 2-2. In vivo passaging with levofloxacin
A) Schematic diagram of in vivo passaging workflow. Seven-week-old BALB/c mice
were intranasally infected TIGR4. Six hours post-infection, mice were administered a
sublethal dose of levofloxacin intraperitoneally. Twelve hours after levofloxacin
treatment, bacteria were collected from lungs of infected mice. Bacteria from the lungs
were spread plated on blood agar plates for 12 hours, and frozen in aliquots containing
glycerol. Frozen aliquots from each passage served as the inoculum to infect the next
group of mice for the subsequent, respective lineage, and the remaining aliquots were
used for genomic DNA extraction. B) in vivo passaging. Bacteria burden was enumerated
after each passage under levofloxacin pressure.
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Table 2-3.

MIC of evolved isolates from in vivo passaging
Strains
TIGR4
L1, G29, N0*
L2, G29, N0
L3, G29, N0

MIC (µg/mL)
1
1.5
1.5
1.5

*L1, G29, N0 denotes bacterial lineage 1, generation (passage 29), non-depleted mice,
respectively.
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Extremely low transformation efficiency suggests infrequent horizontal acquisition
of fluoroquinolone resistance determinants in S. pneumoniae
Besides de novo mutations, fluoroquinolone resistance in S. pneumoniae can
occur via horizontal transfer. Horizontal transfer (specifically transformation) promotes
the rapid spread of resistance in S. pneumoniae [84]. However, the low prevalence of
fluoroquinolone-resistant clinical isolates despite high usage suggests that horizontal
transfer of fluoroquinolone resistance determinants might not occur as readily as
expected. To determine the transformation frequency of horizontal transfer of
fluoroquinolone on-target resistance determinants in S. pneumoniae, we transformed the
wild-type TIGR4 with PCR fragments encoding a single mutation in either on-target
genes, S81F in gyrA or S79Y in parC and selected transformant colonies on 1x MIC of
ciprofloxacin (Figure 2-3A-I) or 1x MIC of levofloxacin (Figure 2-3J-R). The on-target
mutations were selected for the transformation experiments because they are often
screened for and highly prevalent in fluoroquinolone-resistant clinical isolates [85-89].
As shown in Figure 2-3A and J, transformation with single on-target point mutations
with the wild-type TIGR4 did not readily occur. When transformation did occur, the
transformation efficiency was very low ranging from 10-8 to 10-5 CFU/mL per 5 µg DNA
of PCR fragments encoding either S81F in gyrA or S79Y in parC. Based on previous
studies on competence of S. pneumoniae, the transformation efficiency ranges from 10-8
to 10-7 per nucleotide [81]. For our positive control, the wild-type TIGR4 received
genomic DNA of a group of S. pneumoniae mutants that have transposon insertions in
non-essential genes in S. pneumoniae (Tn-seq library) and the spectinomycin-resistance
cassette used for transformants selection. This positive control was expected to have a
much higher chance of transformation and would demonstrate that the bacteria were
competent during transformation. As expected, the transformation efficiency of TIGR4
with the Tn-seq library was consistent at 104 CFUs/mL per 5 µg DNA, suggesting that
the bacteria were competent during the transformation experiments. Therefore, the low
transformation efficiency observed with on-target mutations for fluoroquinolone
resistance was not due to lack of the bacterial competence, but likely due to the
deleterious fitness costs associated with those mutations (Figure 2-3A and J). The
negative control contained no DNA to ensure that fluoroquinolone resistance was
conferred by the incorporation of the single mutation in parC or gyrA from the added
PCR fragments and not by encoding spontaneous mutations in those genes. No
spontaneous mutants were observed in our negative control (Figure 2-3A and J). To
determine whether this low transformation efficiency is serotype-specific, we also
transformed other S. pneumoniae serotypes that are observed in the clinical setting, D39
serotype 2 (Figure 2-3D and M), and CDC001 serotype 9V, and observed similar
transformation efficiencies (Figures 2-3 G and P). These data indicate that there may be
barriers to horizontal transfer for fluoroquinolone resistance as single on-target point
mutations alone were insufficient to transform TIGR4, CDC001 (serotype 9V), or D39
(serotype 2) strains to acquire fluoroquinolone resistance. Thus, low transformation
frequency occurred in multiple serotypes of S. pneumoniae.
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Figure 2-3. Low transformation efficiency for FQ resistance determinants was
observed in TIGR4, D39, and CDC001 serotypes
Single-point mutation recombinants included S79Y parC or S81F gyrA .Tn-seq library
served as positive control for S. pneumoniae baseline for competency. S. pneumoniae
clinical isolates include isolates 188, 68, 66, 93, 112, 114, 176, and 182. S. viridans
clinical isolates include isolates 1-20. A-I. Transformants were selected on 1x MIC
ciprofloxacin. A, D, and G) Transformation efficiency of TIGR4, D39, and CDC001
(serotype 9V), respectively, with PCR fragments encoding on-target mutations in parC
and/or gyrA. B, E, and H. Transformation efficiency of TIGR4, D39, and CDC001
(serotype 9V), respectively, with genomic DNA of fluoroquinolone-resistant
pneumococcal clinical isolates. C, F, and I) Transformation efficiency of TIGR4, D39,
and CDC001 (serotype 9V), respectively, with genomic DNA of fluoroquinoloneresistant S. viridans clinical isolates. J-R) Transformants were selected on 1x MIC
levofloxacin. Similar formats as A through I figures regarding recipient strains and DNA
donors. Transformation with genomic DNA of Tn-seq library served as a positive control
for competence. Transformation efficiency was calculated as the ratio of the number of
transformants (CFUs/mL) selected on either ciprofloxacin or levofloxacin to the number
of total bacteria (CFUs/mL).
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Compensatory mutations in the genome have been shown to ameliorate fitness
costs imparted by on-target mutations, thereby facilitating the acquisition as well as
allowing them to fixate in the population [90, 91]. We sought to examine whether the
fluoroquinolone resistance determinants along with potential compensatory mutations in
the genome of fluoroquinolones resistant S. pneumoniae clinical isolates could increase
the transformation efficiency and facilitate the acquisition of fluoroquinolone resistance.
Even with potential compensatory mutations in the genomic DNA of the resistant S.
pneumoniae isolates, the transformation efficiency of TIGR4, D39, and CDC001
remained extremely low (Figure 2-3B, E, H, K, N, and Q). Transformation with
genomic DNA of the resistant intraspecies isolates that encoded double point mutations
in both parC and gyrA occurred more often than those with genomic DNA that encoded
only single point mutation in either parC or gyrA. Another major reservoir of antibiotic
resistance determinants for S. pneumoniae was viridans group streptococcal clinical
isolates [92]. We attempted to determine the transformation efficiency of S. pneumoniae
with the interspecies genomic DNA from resistant viridans group clinical isolates. Most
of the fluoroquinolone-resistant viridans group streptococcal clinical isolates, which we
obtained from the clinical microbiology laboratory at SJCRH, encoded double point
mutations in both gyrA and parC except isolate #5 having triple point mutations in gyrA,
gyrB, and parC. Transformation with genomic DNA of fluoroquinolone-resistant viridans
group streptococci still rarely occurred. The TIGR4 strain was transformed with isolates
16, 17, and 18, which encoded double point mutations in parC and gyrA at 10-7 per 5 µg /
DNA (Figures 2-3C and L). No transformants were observed from the transformation
with D39 and CDC001 strains (Figures 2-3F, I, O, and R). Taken together, infrequent
transformation efficiencies with both intra- and inter-species genomic DNA encoding ontarget mutations for fluoroquinolone resistance and potential compensatory mutations
corroborate that there are barriers to acquisition of fluoroquinolone resistance
determinants via horizontal transfer in S. pneumoniae.

Individual fluoroquinolone resistance mutations impose severe fitness defects in
vitro that are likely alleviated upon secondary mutation
A key factor that determines whether a resistant strain will survive and
disseminate in the environment or in the host is the fitness cost associated with the
mutation(s) [91]. In S. pneumoniae, fitness refers to the ability of the bacteria to colonize,
replicate, invade different bodily organs, and disseminate to other hosts [93]. As
previously mentioned, the extremely low transformation efficiency of S. pneumoniae
with only on-target mutations for fluoroquinolones resistance suggest that those
mutations likely impose deleterious fitness costs. Without antibiotic pressure, mutations
that confer antibiotic resistance but carry high fitness costs are less likely to persist in the
population [54, 56]. Therefore, we hypothesized that mutations likely to emerge in
clinical settings are those with resistance potential and the least fitness tradeoffs during in
vitro growth as well as in vivo challenge. To test this hypothesis, we generated singleand double-point mutants via transformation with a PCR fragment encoding the desired
mutation(s). We successfully generated single point mutants S79Y parC and S81F gyrA,
and double point mutants S79Y parC & S81F gyrA, and S79Y parC & D435N gyrB via
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transformation with PCR fragments encoding specific mutations and confirmed the
presence of those mutations without any other on-target mutations via whole genome
sequencing. During the transformation, the single point mutants received one type of
PCR fragments encoding either S79Y parC or S81F gyrA mutation, whereas the double
point mutants S79Y parC & S81F gyrA received a mixture of two types of PCR
fragments (each type encoded either of the mutations). These mutations have been shown
to confer high-level resistance to fluoroquinolones and circulate in the clinical setting
[72, 94-96]. The encoded mutations decreased the susceptibility of the bacteria to
ciprofloxacin and levofloxacin. The MICs of ciprofloxacin and levofloxacin of TIGR4
were 4 and 2 µg/mL, respectively (Table 2-2). While single point mutants S79Y parC
and S81F gyrA and the double point mutant S79Y parC & D435N gyrB were able to
grow on blood agar plates supplemented with 4 µg/mL ciprofloxacin or 2 µg/mL
levofloxacin, the double point mutant S79Y parC and S81F gyrA was able to grow at 8
µg/mL ciprofloxacin and 4 µg/mL levofloxacin. We then compared the growth rates of
the single point mutants S79Y parC and S81F gyrA, and double point mutants S79Y
parC & S81F gyrA, and S79Y parC & D435N gyrB in the absence of antibiotic pressure.
The single on-target mutants S79Y parC and S81F gyrA demonstrated marked delay in
growth compared to the wild-type TIGR4 (Figure 2-4A). Interestingly, the double
mutant S79Y parC & S81F gyrA had similar growth rate to that of the wild type, while
the double mutant S79Y parC & D435N gyrB had the similar growth pattern to that of
the S79Y parC mutant (Figure 2-4A).
Next, we determined the fitness of the single and double mutants by determining
their virulence in murine models. For our pneumococcal virulence model, we intranasally
infected 6-week-old BALB/c mice with high-volume inoculum (106 CFUs in 100 µL)
containing the susceptible, parental TIGR4 strain or the single on-target mutations in
gyrA and/or parC or the double mutants. At 24 hours post challenge, we collected nasal
and blood samples via nasal lavage and tail bleeding, respectively. Compared to the wildtype TIGR4, the single mutants with a point mutation in either gyrA or parC displayed
attenuated virulence. Unlike the single mutant in gyrA, the single mutant in parC was
able to colonize the nasopharynx as effectively as the wild type (Figures 2-4B and C).
Although there was 1 log decrease in bacterial burden compared to the wild type, the
double point mutant S79Y parC and S81F gyrA still adequately colonized the
nasopharynx (Figures 2-4B and C). Both the single mutants S79Y parC and S81F gyrA
were not detected in the bloodstream, indicating that they were not able to disseminate
and/or survive in the bloodstream to cause invasive disease (Figures 2-4D and E). In
addition to measuring bacterial burden in the nasopharynx and blood, we monitored
infected mice for survival for 10 days. Mice infected with the single point mutants S79Y
parC and S81F gyrA and the double point mutant S79Y parC & D435N gyrB showed a
significant increase in survival compared to those infected with TIGR4 (Figures 2-4F -I).
Loss of virulence of the single point mutants and the double points mutant S79Y parC &
D435N gyrB was consistent with their undetectable bacterial burden in the blood.
However, mice infected with the double point mutant S79Y parC & S81F gyrA initially
had reduced mortality but eventually succumbed to infection compared to mice infected
with the wild type (Figure 2-4H). The in vitro growth and virulence phenotype of the
double point mutant S79Y parC & D435N gyrB resembled that of the single parC
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Figure 2-4. Fitness defect was demonstrated in vitro and in vivo (blood) with single-point mutation recombinants of parC
and gyrA, and in vivo (nasal swish) with single and double point mutants
The recombinants' CFUs/mL were compared to that of the respective wild-type strains via the non-parametric Mann-Whitney t-test. *p
< 0.05, **p < 0.01, ****p < 0.001. Bars represent SEM. A) Growth curves in vitro in semi-chemically defined media (C+Y). B and C)
Nasal lavage 24 and 48 hours p.i.,respectively. D and E) Blood titers 24 and 48 hours p.i, respectively. F) Survival curves of TIGR4
and S79Y parC mutant. G) Survival curves of TIGR4 and S81F gyrA mutant. H) Survival curves of TIGR4 and S79Y parC & S81F
gyrA double point mutant. I) Survival curves of TIGR4 and S79Y parC & D435N gyrB double point mutant
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mutant, suggesting that the fitness costs and transcriptional changes were mediated
mainly by the parC mutation (Figure 2-4). Here, the single on-target mutations in either
gyrA or parC imposed deleterious fitness costs, while double mutations in both target
enzymes maintained virulence similar to the wild type. These results suggest that the
acquisition of mutations in only one of the on-target enzymes (gyrA or parC) is
associated with detrimental fitness costs manifested in the attenuation of S. pneumoniae
TIGR4. Detrimental fitness costs imposed by the individual on-target mutations in parC
and gyrA likely attribute to the limited transformation efficiencies with fluoroquinolone
resistance determinants. Acquisition of those on-target mutations might have successfully
occurred, but transformants could not survive and propagate due to the fitness costs.
Therefore, deleterious fitness costs represent an important barrier to the acquisition of
fluoroquinolone resistance via horizontal transfer in S. pneumoniae.

Combination of levofloxacin and host pressure induced tolerance phenotype rather
than high-level resistance
The absence of on-target mutations for fluoroquinolone resistance and resistance
development in the experimentally evolved isolates led us to examine whether the
isolates displayed tolerance phenotype. Although there is still no clear standardized
measure for tolerance as for resistance, one method to determine tolerance is by
conducting kill curves. Tolerant strains, by definition, can survive transient exposure to
high antibiotic concentrations that are otherwise lethal, thereby having slower kill
kinetics than susceptible strains [44]. The experimentally-evolved isolates were
eliminated more slowly than the wild type at lethal concentrations of levofloxacin (1x
and 2x MICs) (Figures 2-5A and B). This confirmed that the experimentally-evolved
isolates developed tolerance instead of resistance to levofloxacin under the antibiotic and
the host’s immune pressure. We next tested whether the experimentally-evolved isolates
also conferred cross-tolerance to other clinically-relevant fluoroquinolones, such as
ciprofloxacin and moxifloxacin. Compared to the wild-type TIGR4, the isolates exhibited
similar killing kinetics in both ciprofloxacin and moxifloxacin (Figures 2- 5C, D, E, and
F). This indicates that the isolates did not confer cross-resistance to other fluoroquinolones and that their tolerance phenotype was specific only to the antibiotic in which
they were previously passaged.
From the whole genome sequencing data of the passaged isolates, we identified
mutations that most likely conferred tolerance as those that arose in more than one
independent lineage, were absent prior to in vivo passaging, and fixated in the bacterial
population at high frequencies. Mutations in isochorismatase arose in three independent
lineages during in vivo passaging with levofloxacin, starting in passage 8-10 and
remaining in the population (Figure 2-6). Examples of those mutations are A44D, A4D,
and H172D (Figure 2-6 and Appendix). Mutations in pyruvate oxidase (M1T, Q456*)
and chlorohydrolase (Q17*, F19V) occurred in subsequent passages and remained in the
population until the final passage in two lineages (Figure 2-6). The missense mutation in
the start codon M1T and the nonsense mutation Q456* in the pyruvate oxidase gene
would very likely result in a non-functional and truncated protein product of this gene.
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Figure 2-5. Experimentally-evolved isolates of S. pneumoniae exhibited tolerant
phenotype to levofloxacin
A and B) Kill curves conducted with 1x MIC and 2x MIC of levofloxacin,
respectively.T4 316 (blue) is the wild type. T4 316 L1-L3, G29, Nd (red) represent 3
independent evolved lineages in immunocompetent mice. C and D) Kill curves with
ciprofloxacin at 1x MIC and 2x. E and F) moxifloxacin at 4x and 8x MIC respectively.
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Figure 2-6. Muller plots representing relative abundance of selected mutations arose in multiple lineages during in vivo
passaging with levofloxacin
A) Lineage 1. B) Lineage 2. C) Lineage 3.
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Those mutations in isochorismatase, pyruvate oxidase, and chlorohydrolase are off-target
mutations. The absence of on-target mutations in GyrA and ParC likely explains the lack
of fluoroquinolone resistance observed in the experimentally-evolved isolates. Although
tolerance has been shown to rapidly lead to resistance [97], the tolerant experimentallyevolved isolates did not increase transformation efficiency. The result suggests that in our
case, tolerance did not facilitate horizontal transfer of fluoroquinolone resistance
determinants (data not shown). Perhaps, the off-target mutations were more advantageous
than the on-target mutations by allowing the bacteria to transiently evade levofloxacin
and immune clearance without compromising bacterial fitness.

The evolved isolates from in vivo passaging produced significantly lower production
of H2O2
Besides the on-target inhibitions, fluoroquinolones have been shown to exert
redox stress on bacteria [98]. Dwyer et. al. demonstrated that norfloxacin (a first-class
fluoroquinolone and an inhibitor of Gyrase A) increased the generation of hydroxyl
radicals via superoxide generation in E. coli [39]. Hence, in the presence of
fluoroquinolone, the bacteria are under redox stress from two major sources: their own
H2O2 product and fluoroquinolone-induced radicals. The nonsense and missense
mutations in the pyruvate oxidase identified from whole genome sequencing analysis led
us to assess H2O2 production among the evolved isolates and if altered production of
H2O2 could contribute to the tolerance phenotype observed in the isolates. Using the
Amplex Red Hydrogen Peroxide/Peroxidase assay kit, we measured H2O2 production in
each strain. The ∆spxB∆lctO double knockout served as a negative control because it has
been shown to produce very little H2O2 [99]. Compared to TIGR4, all three evolved
isolates from the in vivo passaging produced significantly less H2O2 (Figure 2-7). This
phenotype is likely attributed to the nonsense and missense mutations, suggesting the
lack of pyruvate oxidase activity among these evolved isolates. As lower H2O2
production lessens the redox stress burden, it is possible that the bacteria are now able to
manage fluoroquinolone-derived redox stress more effectively, thereby withstanding the
antibiotic killing via tolerance.

Striking similarities were observed in the transcriptional profiles in the double point
mutant S79Y parC & S81F gyrA and in the wild-type TIGR4
To understand the mechanism(s) underlying the attenuation of the single on-target
point mutants in parC and gyrA, we next sought to ascertain differences in the
transcriptional profiles of those single- and double-point mutants compared to the wildtype TIGR4 in S. pneumoniae in the absence of fluoroquinolones by utilizing RNA-seq.
The S81F gyrA mutant upregulated multiple enzymes and transporters responsible for the
metabolism of different monosaccharides, such as glucose, fructose, and mannose,
approximately 2.7 to 5.7 log2 fold change (Table 2-4). Alpha, alpha-phosphotrehalase
was downregulated at -5.83 log2 fold change. This enzyme participates in starch and
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Figure 2-7. The evolved isolates produced minimal H2O2
H2O2 production was measured using the Amplex Red kit. ∆spxB∆lctO double knockout
served as the negative control. Amount of H2O2 was normalized to amount of protein
each respective strain produced. The amount of protein produced was determined via
BCA assay. **p-value < 0.01.
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Table 2-4.

Significant gene expression of the S81F gyrA point mutant vs TIGR4
Annotation

Rhamnulokinase
L-fuculose-phosphate aldolase
Fucose isomerase
YhcH/YjgK/YiaL family protein
PTS sugar transporter subunit IIA
Sugar ABC transporter permease
PTS sugar transporter subunit IIB
Sugar ABC transporter substrate-binding protein
N-acetylmannosamine-6-phosphate 2-epimerase
PTS mannose/fructose/sorbose/N-acetylgalactosamine
transporter subunit IIC
PTS mannose/fructose/sorbose transporter family subunit IID
LacI family transcriptional regulator
Glycoside hydrolase family 32 protein
PTS beta-glucoside transporter subunit IIBCA
Iron-containing alcohol dehydrogenase
Glycoside hydrolase family 95 protein
Hypothetical protein
Sugar ABC transporter permease
PadR family transcriptional regulator
PTS transporter subunit EIIC
Carbohydrate ABC transporter permease
Sugar ABC transporter permease
Extracellular solute-binding protein
UDP-glucose--hexose-1-phosphate uridylyltransferase
Carbohydrate ABC transporter permease
Sucrose phosphorylase
PTS system trehalose-specific EIIBC component
PI-1 pilus system sortase SrtC-3
PI-1 pilus system sortase SrtC-2
PI-1 pilus transcriptional regulator RlrA, transcriptional
regulator (positive regulator)
PI-1 pilus system sortase SrtC-1
Alpha, alpha-phosphotrehalase
RrgC pilus, LPXTG cell wall anchor domain-containing protein
RrgB pilus, isopeptide-forming domain-containing fimbrial
protein
RrgA pilus, VWA domain-containing protein
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Log2 Fold Change
5.79
5.08
4.51
4.34
4.27
4.23
4.01
3.69
3.60
3.57
3.42
3.34
3.25
3.04
2.92
2.92
2.81
2.72
2.70
2.59
2.51
-2.69
-2.69
-2.77
-2.90
-3.22
-3.48
-4.57
-4.69
-4.75
-4.96
-5.09
-5.74
-5.83
-6.07

sucrose metabolism (Table 2-4). Furthermore, downregulation of UDP-glucose-hexose1-phosphate uridylyltransferase, which is an enzyme involved in nucleotide sugars
metabolism, was observed (Table 2-4). Those sugar metabolic enzymes also participate
in the nucleotide synthesis pathway. In contrast to the S81F gyrA mutant, the S79Y parC
mutant did not significantly alter its metabolic transcriptional response. A marked change
was the downregulation of its competence-stimulating peptide comC and ATP-dependent
Clp protease ATP-binding subunit at -2.72 and -4.01 log2 fold change (Table 2-5).
Isoleucine-tRNA ligase was upregulated at 2.97 log2 fold change (Table 2-5). Similar to
the transcriptional profile of the S79Y parC mutant, the profile of S79Y parC & D435N
gyrB mutant showed downregulation of Clp protease ATP-binding subunit. Molecular
chaperones DnaJ and DnaK were also downregulated at -2.54 and -3.13 log2 fold change
(Table 2-6). Again, these results suggest that the transcriptional changes and decreased
virulence observed in the double point mutant S79Y parC & D435N gyrB are primarily
due the S79Y mutation in parC and not from D435N mutation in gyrB. The
transcriptional profile of the double point mutant S79Y parC & S81F gyrA almost
resembled that of the wild type, except the downregulation of 4 genes, Gfo/Idh/MocA
family oxidoreductase, sugar ABC transporter substrate-binding protein, neuraminidase
NanB, and YhcH/YjgK/YiaL family protein (Table 2-7). There were not many
significant alterations in the transcriptional profiles of the double mutant compared to that
of the wild type. The double point mutant S79Y parC & S81F gyrA restored virulence to
the level of the wild type. This could explain the similarities in their virulence and
common prevalence in clinical setting. It also suggests that clinically relevant, high-level
fluoroquinolone likely requires the specific combination of on-target mutations in ParC
and GyrA.

Discussion
In this study, we aimed to investigate the discrepancy between high usage rate of
fluoroquinolones and the low resistance rate of this class of antibiotic. We found that the
single- and double-point mutants in the target enzymes, topoisomerase IV parC and DNA
gyrase gyrA, generated via transformation exhibited comparable MICs to those of clinical
isolates. However, there were severe fitness costs associated with the acquisition of
fluoroquinolone resistance determinants in S. pneumoniae via horizontal transfer unless
double point mutations in GyrA and ParC were acquired simultaneously
(Figure 2-3A, D, G, J, M, and P). The fate of a resistance mutation in the bacterial
population depends on the balance of the resistance potential that the mutation confers
versus the fitness costs of maintaining that mutation. Mutations in on-target enzymes that
circumvent the antibiotic’s mechanism of actions often disrupt important cellular
processes, such as cell wall synthesis, protein synthesis, and DNA replication, in which
parC and gyrA participate. Clinical studies report that high-level fluoroquinolone
resistant S. pneumoniae isolates often harbor double point mutations in ParC and GyrA
[100-102]. The presence of the on-target double point mutant in clinical settings is
consistent with our finding that the double point mutant exhibited high resistance
potential with low fitness costs, while maintaining virulence level similar to that of the
wild type [103]. Rozen and colleagues also reported that the second mutations in either
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Table 2-5.

Significant gene expression of the S79Y parC point mutant

Annotation
LPXTG cell wall anchor domain-containing protein
Isoleucine--tRNA ligase
Isopeptide-forming domain-containing fimbrial protein
VWA domain-containing protein
Competence-stimulating peptide ComC
ATP-dependent Clp protease ATP-binding subunit

Log2 Fold Change
3.05
2.97
2.92
2.55
-2.72
-4.01

Table 2-6.
Significant gene expression of S79Y parC & D435N gyrB double point
mutant vs TIGR4
Annotation
Isoleucine--tRNA ligase
PI-1 pilus tip adhesin RrgA, VWA domain-containing protein
PTS system mannose/fructose/N-acetylgalactosamine-transporter
subunit IIBchaperone DnaK
Molecular
IS200/IS605-like element ISSpn6 family transposase
ATP-dependent Clp protease ATP-binding subunit
Molecular chaperone DnaJ
tRNA

Table 2-7.

Log2 Fold Change
2.74
2.54
-2.54
-2.54
-2.61
-3.08
-3.13
-4.15

Significant gene expression of S79Y parC & S81F gyrA vs TIGR4

Annotation
Gfo/Idh/MocA family oxidoreductase
Sugar ABC transporter substrate-binding protein
Neuraminidase NanB
YhcH/YjgK/YiaL family protein
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Log2 Fold Change
-2.72
-3.55
-3.69
-4.26

ParC or GyrA not only increased resistance potential but also lessened the fitness costs
associated with fluoroquinolone resistance mutation(s) [104]. The high fitness costs
imparted by the on-target mutations that confer fluoroquinolone resistance partly explain
the low prevalence of fluoroquinolone resistance. The transformation frequency in S.
pneumoniae is approximately 10-7 to 10-8 per nucleotide [81]; therefore, the frequency of
acquiring both on-target mutations is tremendously reduced to approximately 10-14 per
nucleotide. Therefore, the infrequent fluoroquinolone resistance is likely attributed to the
combination of extremely low rate of acquisition of both double point mutations in parC
and gyrA via horizontal transfer and the fitness costs that limit the dissemination of single
point mutants. These results indicate that successful acquisition and dissemination of
fluoroquinolone resistance in S. pneumoniae requires a balance between resistance
potential and fitness costs.
We next focused on elucidating the underlying mechanism associated with the
deleterious fitness costs imparted by the on-target mutations for fluoroquinolone
resistance by examining the transcriptional profiles of the mutants in the absence of
fluoroquinolones (Tables 2-4 to 2-7). Downregulation of alpha, alpha-phosphotrehalase
and UDP-glucose-hexose-1-phosphate uridylyltransferase responsible for nucleotide and
sugar metabolism in the single point mutant S81F gyrA suggests that once gyrA is
mutated, nucleotides metabolism for DNA replication and downstream protein synthesis
must be reduced to maintain homeostasis. Nucleotides are generally energetically costly
and must be conserved efficiently [105, 106]. As DNA replication is disrupted due to the
mutation in gyrA, nucleotides could accumulate, and excess in nucleotides could then
inhibit DNA replication and protein synthesis as a negative feedback mechanism.
Inhibited DNA replication likely results in reduced growth rates, causing the bacteria to
be eliminated more rapidly by the host’s immune responses, hence their attenuation in
virulence. Furthermore, transcriptional changes in carbohydrates metabolism incurred by
the on-target mutations likely limit survival and dissemination of S. pneumoniae to
different host’s niches. Based on the RNA-seq analysis, sugar metabolism was one of the
transcriptional responses altered due to the on-target mutations for fluoroquinolone
resistance. Most transcriptional alterations in sugar metabolism were detected in the
single point mutant S81F gyrA (Table 2-4). Without a fully functional tricarboxylic
(TCA) cycle and a respiratory electron transport chain, S. pneumoniae relies solely on
fermentation to produce energy by oxidizing carbohydrates [9]. As the bacteria
translocate from the nasopharynx to different host’s niches, they likely encounter
different types of carbohydrates specific to that niche. For example, in inflamed tissues
and blood, glucose is the predominant carbohydrate, whereas in the nasopharynx, free
sugars are limited, but glycans serve as the source of sugars [107, 108]. In order to
effectively disseminate, S. pneumoniae must be able to utilize different sources of
carbohydrates. Therefore, loss of ability to replicate and adapt to different carbohydrates
might be associated with reduced colonization as well as complete attenuation in the
bloodstream.
To understand the mechanisms underlying the development of fluoroquinolone
resistance in vivo, we identified mutations that arose under levofloxacin pressure. During
extensive in vivo passaging, in which the bacteria were under selective pressure from
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both levofloxacin and the host’s immune response, resistance did not occur; instead,
tolerance developed (Figures 2-5A and B). Tolerance was likely induced by the host’s
immune clearance and antibiotic pressure. Whole genome sequencing data provided
insights into the genomic changes that likely confer levofloxacin tolerance. The majority
of the mutations arose in metabolic genes. Actively dividing bacterial processes are
targeted and inhibited by antibiotics [109-111]. Previous studies have shown that tolerant
bacteria inhibit their metabolism and growth to evade antibiotic killing [112]. On-target
mutations for resistance can impart deleterious costs, but mutations for tolerance allow
the bacteria to survive in the host. Tolerance has been shown as a prerequisite pathway
for development of subsequent high-level resistance [97]. Zhang and colleagues
demonstrated that activated PpnN (YgdH) in E. coli participated in the inhibition of
nucleotides synthesis and increase in degradation to confer tolerance to ciprofloxacin and
ofloxacin (a fluoroquinolone) [113]. PpnN is a nucleosidase playing a role in the
metabolism of purine nucleotides; therefore, it is not a direct target of fluoroquinolones.
However, not only does PpnP confer tolerance to fluoroquinolones, but it also offers
fitness advantages during stringent responses to stresses [113]. Therefore, metabolic
changes manifested from the transcriptional changes in those metabolic genes observed
in the experimentally-evolved isolates likely result in antibiotic tolerance.
Taken together, we demonstrated that fitness tradeoffs associated with the
individual on-target mutations in gyrA and parC likely restricted the development of
fluoroquinolone resistance in S. pneumoniae. However, the combination of double point
mutations in gyrA and parC not only restored the fitness of the bacteria but also conferred
a significant increase in fluoroquinolone resistance level. The bacteria developed
tolerance in order to evade antibiotic killing while circumventing the deleterious fitness
tradeoffs. Although it seems quite difficult for fluoroquinolone resistance in S.
pneumoniae to develop, antibiotic stewardship guidelines should be followed to minimize
the emergence and spread of fluoroquinolone resistance in the future due to the transition
from undetected tolerance to resistance. By predicting which mutations have the potential
to facilitate the acquisition of high-level resistance and become clinically important, we
will be able improve surveillance, tailor treatment regimens, and provide insights into the
development of more-effective antibiotics.
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CHAPTER 3. N291D MUTATION IN PATA FACILITATES HORIZONTAL
TRANSFER OF HIGH-LEVEL FLUOROQUINOLONE RESISTANCE
DETERMINANTS

Introduction
Streptococcus pneumoniae is an opportunistic Gram-positive pathogen and a
major cause of hospitalization and mortality in young children and the elderly [3]. S.
pneumoniae causes mild to severe infections, ranging from otitis media, pneumonia,
sepsis, to meningitis. Previously, pneumococcal infections were effectively treated with
commonly prescribed antibiotics, such as beta-lactams, fluoroquinolones, and macrolides
[58]. However, the rapid emergence of antibiotic resistance among S. pneumoniae
isolates has increased treatment failure rates, posing a serious public health problem
worldwide [21]. Antibiotic resistance in S. pneumoniae, including fluoroquinolone
resistance, has spread globally via horizontal transfer of resistance mutations and the
emergence of de novo mutations. Fluoroquinolones inhibit DNA gyrase and topoisomerase IV [37]. The mutations in the main target enzymes GyrA and ParC are ontarget mutations that confer resistance against fluoroquinolones, such as ciprofloxacin
and levofloxacin [114]. On-target point mutations S81F in GyrA and S79Y in ParC have
been found in clinical isolates collected from different areas worldwide, such as in
Canada between 1993 to 1998 [25, 71, 72]. Mutations that occur in genes that are not
directly targeted by the antibiotics, such as genes involved in metabolism, transport, and
regulation of gene expression, are classified as off-target mutations. Current CLSI
guidelines (Clinical & Laboratory Standards Institute) often fail to detect low-level
resistance against fluoroquinolones that fall into the non-susceptible range and do not
screen for off-target mutations. Examples of off-target mutations are ones that mediate
the overexpression of patA and patB, which encode ATP-dependent efflux proteins
clinically relevant for low-level fluoroquinolone resistance in S. pneumoniae [115]. One
efflux pump responsible for low-level fluoroquinolone resistance in S. pneumoniae is
PmrA [116].
Generally, horizontal transfer (specifically transformation) promotes the rapid
spread of resistance in S. pneumoniae. However, the low prevalence of fluoroquinolone
resistant clinical isolates despite high usage suggests that horizontal transfer of fluoroquinolone resistance determinants might not occur as readily as previously thought [117,
118]. Fluoroquinolone resistance in S. pneumoniae is a fascinating case study as isolates
that are resistant to low-level fluoroquinolones sometimes do not have mutations in the
on-target enzymes, topoisomerase IV ParC and DNA gyrase GyrA, suggesting that there
are off-target mutations that contribute to the acquisition and/or exert resistance [119].
Pan et al. showed that mutants that are resistant to low levels of the fluoroquinolone
ciprofloxacin do not require any variations of mutations in the on-target genes [120-122].
Other studies also demonstrated that low-level resistance against fluoroquinolones in S.
pneumoniae does not require on-target mutations, which if subsequently acquired would
confer high-level resistance [123]. Off-target mutation(s) play a role in conferring and/or
facilitating the acquisition of mutations in the antibiotic targets to drive high-level
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resistance and that the fitness tradeoffs incurred by both the off-target facilitator and the
on-target resistance mechanisms will determine whether the mutation will emerge in the
clinic. Whether resistance mutation(s) remain in the bacterial population partly depends
on the balance of the fitness advantage that the mutation confers versus the potential
fitness costs of maintaining the mutation. Therefore, we hypothesized that horizontal
transfer of antibiotic resistance determinants in S. pneumoniae likely requires off-target
mutations besides the on-target mutations.
Clinically, only mutations in the upstream region of patA have been reported and
shown to upregulate the expression of this efflux pump [115, 124]. In this study, we
showed that the N291D mutation in patA slightly increased the transformation efficiency
of both the gyrA and parC mutations that confer high-level resistance for ciprofloxacin.
As such, we concluded that that the mutation in patA likely facilitated the subsequent
acquisition of on-target mutations, thereby serving as a facilitating mutation of high-level
resistance mechanisms. The off-target mutation N291D in patA has never been reported.
The findings of this study will provide insights into the underlying mechanisms that
facilitate the acquisition of high-level antibiotic resistance in S. pneumoniae.

Methods

Growth conditions
Streptococcus pneumoniae (wild-type TIGR4) and TIGR4-derivative point
mutants were incubated on tryptic soy agar (TSA EMD Chemicals) plates containing 20
µg/mL neomycin and 3% sheep blood, in semi-chemically defined C+Y, or in nutrientrich media ThyB supplemented with 5% CO2.The purpose of neomycin supplementation
was to select for S. pneumoniae. Bacterial cultures were inoculated from frozen glycerol
stocks or from bacterial plates incubated overnight. Strains used are listed in Table 3-1.

In vitro passaging
To determine whether the mutation N291D in PatA accelerated the acquisition of
fluoroquinolone resistance, TIGR4 and the point mutants were serially passaged in ThyB
supplemented initially with subinhibitory, increasing concentrations of ciprofloxacin or
levofloxacin. Once the bacteria reached exponential phase OD620 ~0.6, they were
collected, stored in glycerol at -80oC, and used to inoculate the next passage. The bacteria
were exposed to progressively increasing 2-fold dilutions of respective antibiotic in
subsequent rounds of passaging of the antibiotic. The passaging continued for 12 days.
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Table 3-1.

Strains used in this study
Strains

TIGR4

Description
Wild-type S. pneumoniae, serotype 4

∆hexA

hexA knockout

N291D patA

Single point mutant N291D point mutation in patA efflux
pump

S79Y parC & N291D patA

Double point mutant: point mutation S79Y in parC &
point mutation N291D in patA

S81F gyrA & N291D patA

Double point mutant: point mutation S81F in gyrA &
point mutation N291D in patA
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Mutant generation and transformation
The N291D patA point mutant was generated via transformation of TIGR4 the
genomic DNA of the in vitro evolved isolates resistant to the highest concentration of
ciprofloxacin. The point mutant was confirmed via whole genome sequencing. TIGR4
and the N291D patA mutant were incubated in C+Y media to OD620~0.07 to 0.1. Then,
the bacteria received stimulating peptide 2 (CSP-2) [125] and 5 µg of 2 kb PCR fragments encoding either S79Y in topoisomerase IV parC or S81F in gyrA or 5 µg of
genomic DNA of fluoroquinolone resistant S. pneumoniae or viridans clinical isolates.
For selection of transformants, the bacteria were incubated for 3 hours at 37oC
supplemented with 5% CO2, and 100 to 200 µL of the transformation mixture were
spread on blood agar plates supplemented with 1 to 2x MIC of ciprofloxacin or
levofloxacin and incubated overnight at 37oC and 5% CO2. Transformation efficiency
was calculated as the ratio of CFUs/mL of the transformants selected on ciprofloxacin- or
levofloxacin-containing plates to the total number of bacteria grown on blood agar plates.
Single- and double-point mutants were generated via transformation. For the double point
mutants, the N291D patA were successively transformed with the fluoroquinolone
resistance determinants S79Y parC or S81F gyrA. Individual colonies were selected for
whole genome sequencing to confirm the presence of point mutations in parC and gyrA.

qRT-PCR analysis
RNA extraction and qRT-PCR were conducted based on a protocol adapted by
Echlin et al. [126]. Briefly, TIGR4 and the N291D patA mutant were grown in C+Y until
OD620 ~0.4 and exposed to the antibiotics for 30 minutes to 1 hour, and RNA of each
strain was extracted using the QiaShredder, RNeasy Kit (Qiagen), and DNA-free kit
(Thermo Scientific). Then cDNA synthesis was performed using Superscript III First
Strand Synthesis kit (Invitrogen), followed by qRT-PCR with SYBR Green. Fold change
of patA was calculated as 2-∆∆CT.

Fluoroquinolones compound accumulation experiments
S. pneumoniae TIGR4 and N291D patA were inoculated into 500 mL of ThyB
from bacteria grown on blood agar plates overnight. Cultures were grown at 37°C until
mid-log OD600 (0.6-0.8). The bacteria were pelleted at 4,500 x g for 10 minutes at 4°C,
and the supernatant was discarded. The pellets were re-suspended in 20 ml of PBS and
pelleted as before, and the supernatant was discarded. This process was repeated a total of
two times. The pellets were resuspended in 16.6mL of fresh 1x PBS and aliquoted into
1.5 mL Eppendorf tubes (1 mL each). The number of colony-forming units (CFUs) was
determined by a calibration curve. The OD600 of TIGR4 and the mutant were 1.190 and
1.197, respectively. Compound was added to the 1 mL aliquots for a final concentration
of 0.25 mM (25 µL of 10 mM stock or DMSO). Samples were incubated and shaken at
37oC for 10 minutes. After incubation, 800 μL of the cultures were carefully layered on
700 μL of silicone oil (AR20, cooled to -78°C). Each pellet was dissolved in 200 μL of
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HPLC grade water and lysed via beat beating in which approximately 100 µL of bead
were added to the cells and then subject to 3x 45 second beating cycles. Compounds were
extracted by adding 200 µL of HPLC grade methanol. The lysates were pelleted at
13,000 r.c.f. for 2 minutes at room temperature and the supernatant was collected (150
μL). Extracts were allowed to sit at room temperature for an hour to allow for additional
lysate precipitation to occur. This remaining debris was removed by centrifuging at
20,000 r.c.f. for 10 minutes at room temperature. Lysates were spun through a 0.22 µM
filter prior to LC-MS/MS analysis. Bacteria were pelleted through the oil by centrifuging
at 13,000 r.c.f. for 2 minutes at 4oC (supernatant remains above the oil); the supernatant
and oil were then removed by pipetting. Cell pellets were flash frozen and stored at -80oC
until lysis. LC-MS/MS analysis of accumulated compounds were conducted following
our standard small molecule accumulation protocols. MS/MS methods were optimized
for each individual compound.

Virulence studies
To examine virulence of TIGR4 and the point mutants, bacteria were grown in
C+Y to logarithmic phase OD620 ~0.8 and frozen in glycerol stocks at -80oC. Prior to the
infection challenge, the enumerated glycerol stocks were thawed, washed, resuspended in
1x PBS, and diluted to the appropriate concentration for infection. Anesthetized, sevenweek-old female BALB/c mice from Jackson Laboratory were intranasally infected with
30 µL containing 1 x 107 CFUs of TIGR4 or the mutants. After the infection, the infected
mice were monitored for disease progression, including lethargy, conjunctivitis,
meningitis, pneumonia, and bacteremia. At 24 hours post-infection, blood samples, lungs,
and nasal passage were collected via tail-bleeding and dissection, respectively. Bacterial
burden was enumerated by serial dilution in 1x PBS and plating onto blood agar.
Bacterial titers (CFUs/mL) were compared using the non-parametric Mann-Whitney ttest. Mouse survival curves were analyzed using the Kaplan-Meier survival curves and
Mantel-Cox log rank test.

Results

N291D mutation is specific for increasing ciprofloxacin efflux, but not levofloxacin
In this study, we sought to identify mutations that can facilitate the acquisition of
on-target mutations with high-level resistance by generating many possible mutations
involved in fluoroquinolone resistance via in vitro passaging with ciprofloxacin and
identifying mutations via whole genome sequencing (Figure 3-1). The goal of including
∆hexA in the in vitro passaging experiment was to maximize the number of mutations
that potentially confer resistance to ciprofloxacin. Deletion of hexA results in defects in
the mismatch repair system, thereby increasing the mutational frequency [127].
Compared to TIGR4, ∆hexA became resistant to ciprofloxacin at a significantly higher
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Figure 3-1. In vitro serial passaging of TIGR4 and ∆hexA
TIGR4 and ∆hexA were serially passaged in increasing 2-fold dilutions of ciprofloxacin.
Ciprofloxacin MIC of TIGR4 is 4 μg/mL.
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concentration (64 μg/mL), which is equal to the MIC (minimum inhibitory concentration)
of clinical resistant isolates (Figure 3-1) [128]. Because extraneous mutations not related
to ciprofloxacin resistance likely occurred in ∆hexA, we transformed TIGR4 with the
genomic DNA of the most resistant, evolved ∆hexA isolate and selected transformants on
increasing concentrations of ciprofloxacin to identify the mutation(s) underlying
ciprofloxacin resistance. On-target point mutations S81F in gyrA and S79Y in parC were
identified in several evolved isolates. Those on-target mutations have been found in
clinical isolates collected from different areas worldwide [102, 103, 129]. One off-target
mutation of interest was N291D in the efflux pump patA. Clinically, mutations in the
upstream region of patA have been reported and shown to upregulate the expression of
this efflux pump; however, this particular mutation has never been reported. We next
sought to characterize the point mutation N291D in patA. The N291D mutation did not
induce overexpression of patA both in the absence and presence of antibiotics, such as
ciprofloxacin, levofloxacin, and cefepime (Figure 3-2A).
We hypothesized that the mutation could enhance the capacity of the efflux pump
to pump out fluoroquinolones, such as ciprofloxacin and/or levofloxacin. To test this
hypothesis, we measured and compared the intracellular concentration of ciprofloxacin
and levofloxacin of TIGR4 and the N291D mutant under the antibiotic pressure via IMMS. Trimethoprim served as a non-efflux control compound for both strains. Overall, the
intracellular concentration of ciprofloxacin in the N291D mutant decreased 2.62-fold
compared to that of TIGR4 (Figure 3-2B). Only minor reduction in the accumulation of
levofloxacin was observed in the N291D mutant (Figure 3-2B). The mutation did not
affect trimethoprim accumulation (Figure 3-2B). These results indicate that the N291D
mutation in patA arose as a result of the unique adaptation to effectively export
ciprofloxacin.

N291D mutation in patA accelerated the acquisition of on-target mutations in gyrA
and parC for fluoroquinolone resistance in S. pneumoniae
The mutation in patA conferred low level resistance to ciprofloxacin (1xMIC) and
potentially could serve as the first step that allows for the acquisition of clinically
relevant resistance. Next, we sought to investigate whether the N291D patA point mutant
could facilitate the acquisition of high-level fluoroquinolone resistance via horizontal
transfer. We transformed the wild-type TIGR4 and the N291D patA point mutant with 2
kb PCR fragments encoding a single mutation in either on-target genes gyrA or parC and
selected transformant colonies on at least 1xMIC of ciprofloxacin or 1xMIC or
levofloxacin. The negative control contained no DNA to ensure that fluoroquinolone
resistance was conferred by incorporation of the single mutation in parC or gyrA from the
added PCR fragments and not by spontaneous mutations. In contrast, the positive control
(Tn-seq library) received genomic DNA of a group of mutants that have transposon
insertions in non-essential genes in S. pneumoniae. This control should have a much
higher chance of transformation and would demonstrate that the bacteria were competent
during transformation. The similar transformation efficiencies of the wild-type TIGR4
and the N291D patA mutant with genomic DNA of Tn-seq mutants library in the positive
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A

B

Figure 3-2. Characterization of N291D in patA
A) qT-PCR results demonstrated that N291D did not induce overexpression of patA. B)
N291D patA mutant had increased ciprofloxacin efflux but not levofloxacin. Intracellular
concentration of ciprofloxacin and levofloxacin measured via ICP-MS. Trimethoprim
was a non-efflux susceptible comparator. **p-value ⩽0.01. This experiment was
conducted by Stephanie Reeve, PhD from Lee laboratory at St. Jude.
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control showed that the mutation in patA does not increase the bacterial competence. As
shown in (Figure 3-3A and C), transformation with single on-target point mutations with
TIGR4 did not readily occur as the previous studies showed.
When transformation did occurred, the transformation efficiency was very low at
about 10-8 to 10-6 per 5 μg DNA (Figure 3-3A and C). This result indicates that there
may be barriers to horizontal transfer for fluoroquinolone resistance as single on-target
point mutations alone were insufficient to transform the wild type to reach high level of
resistance. Once acquired the single on-target mutations, TIGR4 became resistant to 4
μg/mL of ciprofloxacin (1xMIC). In contrast, the transformation efficiency of the N291D
patA point mutant with the PCR fragments was in the range of 10-8 to 10-3 per 5 µg DNA
(Figure 3-3B and D). The subsequent acquisition of the N291D patA point mutant with
the point mutations in parC and gyrA increased the level of resistance to ciprofloxacin
from 4 μg/mL to 16 μg/mL, 1x to 4x clinical MICs, respectively (Table 3-1). In the
presence of ciprofloxacin, the N291D patA point mutant slightly increased the
transformation efficiency with genomic DNA of fluoroquinolone-resistant pneumococcal
isolates (Figure 3-3E and F). However, no increase in transformation efficiency was
observed in the presence of levofloxacin, which is consistent with our previous finding
that the N291D mutation was specific for ciprofloxacin efflux. These results suggest that
the point mutation N291D in patA potentially facilitated the acquisition of primary target
point mutations in gyrA and parC via horizontal transfer.
Another strategy for S. pneumoniae to acquire fluoroquinolone resistance is
gaining de novo mutations. Therefore, we also determined if the N291D mutant
developed fluoroquinolone resistance more quickly than the wild type by conducting in
vitro passaging, in which the bacteria were exposed to progressively increasing
concentrations of either levofloxacin or ciprofloxacin. During in vitro serial passaging,
the N291D patA mutant displayed resistance against ciprofloxacin at earlier rounds of
passaging than the wild type (Figure 3-4A).Consistent with our previous finding that the
N291D mutation was specific for exporting ciprofloxacin, the mutant did not facilitate
levofloxacin resistance development (Figure 3-4B). Taken together, these data suggest
that the N291D mutation could potentially serve as a stepping stone for subsequent highlevel resistance via both horizontal transfer and de novo mutations, which are two
mechanisms underlying fluoroquinolone resistance in S. pneumoniae.

N291D mutation imparted no fitness costs in S. pneumoniae
Previous results demonstrated that the N291D mutation potentially increased the
acquisition of fluoroquinolone resistance via horizontal transfer and de novo mutation.
We next ascertained if the N291D mutation imposed deleterious fitness costs by
characterizing the growth phenotype in vitro and virulence in the host of the point
mutation. The extent of the fitness costs associated with the mutation N291D determines
the mutant’s potential to disseminate and facilitate the subsequent acquisition of highlevel resistance. The single on-target point mutants S79Y parC and S81Y gyrA displayed
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Figure 3-3. N291D patA mutant likely facilitated the acquisition of ciprofloxacin
via horizontal transfer
A and B) Transformation efficiency of TIGR4 and the N291D patA mutant with PCR
fragments encoding point mutations in parC and gyrA. Transformants were selected on
blood agar plates containing 1x MIC ciprofloxacin. C and D) Transformation efficiency
of TIGR4 and the N291D patA mutant with PCR fragments encoding point mutations in
parC and gyrA. Transformants were selected on blood agar plates containing 1x MIC
levofloxacin. E and F) Transformation efficiency of TIGR4 and the N291D patA mutant
genomic DNA from resistant pneumococcal clinical isolates. Transformants were
selected on blood agar plates containing 1x MIC ciprofloxacin. G and H) Transformation
efficiency of TIGR4 and the N291D patA mutant with genomic DNA from resistant
pneumococcal clinical isolates. Transformants were selected on blood agar plates
containing 1x MIC levofloxacin. Transformation efficiency is the ratio of number of
transformants selected on either ciprofloxacin or levofloxacin. Note: Transformation
efficiency of TIGR4 with ciprofloxacin and levofloxacin serve as the reference and has
been shown in previous study in Chapter 2.
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Figure 3-4. The N291D patA mutant acquired de novo mutation(s) for
ciprofloxacin resistance via more rapidly than the wild type
A) in vitro serial passaging with the N291D patA mutant and TIGR4 under ciprofloxacin
pressure. B). in vitro serial passaging with the N291D patA mutant and TIGR4 under
levofloxacin pressure.
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noticeable growth delays during in vitro growth curve in nutrient-rich C+Y
(Figure 3-5A). Intriguingly, the N291D patA mutant showed similar growth rate to that
of TIGR4 (Figure 3-5A). The double point mutants N291D patA & S79Y gyrA and
N291D patA & S79Y parC grew similarly to TIGR4 until late logarithmic phase
followed by delayed lysis (Figure 3-5A). The N291D patA & S81F gyrA also grew
similarly but lysed more quickly than TIGR4 (Figure 3-5A). To examine the fitness costs
in vivo, we intranasally infected 6-week-old BALB/c mice with high-volume inoculum
(100 μL with 106 CFUs) containing the on-target and/or facilitating mutations or the
susceptible, parental TIGR4 strain. At 24-hour post challenge, we collected nasal and
blood samples via nasal lavage and tail bleeding, respectively. Compared to TIGR4, the
single mutants having a point mutation in either gyrA or parC were generally attenuated
(Figures 3-5B to E). Unlike the single mutant in gyrA, the single mutant in parC was
able to colonize the nasal passage as effectively as the wild type. The single mutant in
patA was able to colonize and was as virulent as the wild type (Figures 3-5B and C).
Interestingly, the double mutants N291D patA & S79Y parC and N291D patA & S81F
gyrA colonized more effectively than the single on-target mutants S81F gyrA or S79Y
parC. This suggests that the mutation in patA reduced the fitness costs of the single ontarget mutants’ that impairs colonization, thereby improving the ability of the single ontarget mutants to colonize and possibly increasing the chances of the bacteria to acquire
higher levels of resistance. Both the single on-target mutants in gyrA or parC were not
detected in the bloodstream, indicating that they were not able to disseminate and/or
survive in the bloodstream to cause invasive disease (Figures 3-5D and E). The N291D
mutation in patA was able to ameliorate the fitness costs of the on-target parC mutation
in terms of of invasiveness (Figures 3-5D and E). Both the single on-target mutants in
gyrA or parC were not detected in the bloodstream, indicating that they were not able to
disseminate and/or survive in the bloodstream to cause invasive disease. These results
suggest that the horizontal acquisition of mutations in only one of the on-target enzymes
(gyrA or parC) acquired via transformation is associated with high fitness costs, thus
rendering the susceptible phenotypes in vivo. However, once facilitating mutation(s)
without considerable fitness costs emerges, they could promote further acquisition of ontarget mutations to drive clinically significant resistance without loss of fitness.

Discussion
In this study, we attempted to identify potential off-target mutation(s) that not
only conferred low-level fluoroquinolone resistance but also accelerated subsequent
acquisition of high-level fluoroquinolone resistance in S. pneumoniae. We specifically
characterized a novel mutation N291D in the efflux pump patA in regard to its
contribution to fluoroquinolone resistance in S. pneumoniae. The transformation
efficiency results indicated that the mutation N291D likely served as a facilitator
mutation that promoted the acquisition of on-target mutations and that, together, they
conferred high level of fluoroquinolone resistance. This mutation in the efflux pump
likely decreased the intracellular concentration of the antibiotic, which offered the
bacteria a survival advantage that then led to the accumulation of more mutations
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Figure 3-5. The N291D patA mutant had negligible effects on in vitro growth rate
and virulence in an intranasal murine infection model
Six-week old BALB/c mice were infected intranasally 100 μL containing 1x106 CFUs.
A) in vitro growth curves. B) Nasal lavage 24 hours post-infection. C) 48 hours postinfection. D) Blood titers 24 post-infection. E) Blood titers 48 post-infection. **pvalues⩽ 0.01; ***p-values⩽ 0.001; ****p-values⩽ 0.0001.
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subjected to selection for fluoroquinolone resistance. Furthermore, the N291D did not
impart any fitness costs in vivo, thereby enabling the bacteria to disseminate in clinical
setting and enhancing the likelihood of subsequent acquisition of fluoroquinolone
resistance development via horizontal transfer and/or de novo mutations. However, our
finding that the high specificity of the mutation for ciprofloxacin instead of levofloxacin
is consistent with that of Avrain et al. that PatA and PatB efflux pumps do not transport
levofloxacin [130]. Taken together, the N291D mutation in patA once in clinical setting
circulating likely poses a dangerous impetus for the emergence and spread of
fluoroquinolone resistance by having minimal fitness costs, enhanced likelihood for the
bacteria to obtain subsequent mutation for high-level resistance and remaining
undetectable by current standard clinical testing.
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CHAPTER 4. INTERSPECIES RECOMBINATION EVENTS CONFER
POTENTIAL VIRULENCE AND FITNESS ADVANTAGES OVER DE NOVO
MUTATIONS IN BETA-LACTAM RESISTANT STREPTOCOCCUS
PNEUMONIAE

Introduction
Streptococcus pneumoniae remains a major human pathogen causing pneumonia,
otitis media, bacteremia and meningitis in both children and adults. Globally, an
estimated 300,000 deaths in children were attributed to pneumococcal infection in 2015,
despite the introduction and use of pneumococcal conjugate vaccines [57]. Additionally,
pneumococcal resistance to antibiotics in the United States has not appreciably decreased
over the past few years, with resistance estimates hovering, for example, between 2% 2.4% for penicillin over the past 5 years [131-134]. In 2019 alone, drug-resistant S.
pneumoniae was responsible for an estimated 900,000 infections and 3,600 deaths and
has been designated as a serious threat by the Center for Disease Control [135].
Moreover, β-lactam antibiotics are among the most commonly utilized drugs to treat
pneumococcal infection, and while there is ongoing debate on the clinical impact on
mortality and illness severity with β-lactam resistant S. pneumoniae [136, 137], it remains
important to understand the mechanisms by which resistance can arise.
S. pneumoniae is a naturally competent pathogen, able to readily uptake genomic
material from neighboring pneumococcal cells and closely related streptococcal species
[30, 138, 139]. Consequently, the pneumococcus can utilize this ability to gain resistance
via alterations in the genes encoding drug targets, such as the penicillin-binding proteins
(PBPs) [30, 140, 141]. Importantly, previous work had identified recombination events,
as opposed to spontaneous single nucleotide polymorphisms, as the major driver of rapid
resistance acquisition [142]. Indeed, commensal streptococcal species resistant to
penicillin and other β-lactams have been identified as reservoirs with which S.
pneumoniae can recombine [143, 144]. However, genomic recombination in response to
drug selective pressure can often result in virulence and fitness defects in exchange for
drug-resistance [145, 146]. Therefore, understanding the consequences of these
resistance-acquiring recombinations and the determinants driving this selection are
critical to studying antibiotic resistance.
Here, we propose that steep fitness trade-offs associated with de novo mutations
restrict their emergence in pneumococcal populations in response β-lactam exposure and
that horizontal transfer of resistance genes via interspecies recombination may be
preferable due to reduced fitness tradeoffs. Using β-lactam-resistant recombinant
pneumococcal strains, we observed enhanced virulence in vivo with initial recombinant
strains compared to antibiotic-evolved resistant pneumococcal strains possessing de novo
point mutations. While in vitro characterization revealed only modest differences in
adherence to mammalian cells, invasive potential, macrophage phagocytosis, and affinity
for penicillin-binding proteins between strains, recombinant strains demonstrating initial
small MIC increases were comparably virulent to wild type parent strains and exhibited
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roughly equivalent bacterial burden within the blood, lung tissue, and colonization in the
nasal passages. Sequencing of strains revealed fairly sizeable regions of apparent
recombination, including a conserved pattern of recombination around the PBP2X locus
in all recombinant strains tested. These findings indicate that horizontal gene transfer, as
opposed to de novo mutation, is easily achievable and grants decreased susceptibility to
β-lactams without a significant in vivo cost in S. pneumoniae.

Methods

Strains and growth conditions
Streptococcus pneumoniae was inoculated from frozen glycerol stocks onto
tryptic soy agar (TSA Milipore Sigma) plates containing 20 µg/mL neomycin and 3%
defibrinated sheep blood and then incubated overnight at 37oC with 5% CO2. Because S.
pneumoniae is naturally resistant to neomycin, it was added to prevent contamination of
other bacterial species. Liquid cultures using semi-defined media C+Y or ThyB (Todd
Hewitt Broth BD 249240) and 2% yeast extract (BD 212750) were inoculated with the
bacteria grown on the blood agar plate [147].

Epsilometric MIC determination
Bacterial strains were inoculated into C+Y from overnight growth on agar plates
and incubated at 37oC with 5% CO2 until reaching mid-logarithmic phase at OD620 ~0.4.
Then, 100 µL of the bacterial culture were spread plated on blood agar plates
supplemented with neomycin before E-test strips (bioMerieux) were added onto the
center of the plates. Plates were incubated overnight at 37oC with 5% CO2. MIC was
determined in terms of µg/mL where the symmetrical inhibition ellipse edge intersected
the E-test strips on the plate. The recombinant strains were tested with either penicillin or
cefepime as representative β-lactam antibiotics.

Recombinant pneumococcal strain generation and transformation
TIGR4 and D39 were grown in C+Y media to OD620 ~ 0.07 to 0.1. Genomic
DNA from penicillin- or cefepime-resistant S. pneumoniae or S. viridans strains and the
competence stimulating peptide 2 or 1 (CSP-1 or 2) were added to TIGR4 or D39
cultures, respectively [125]. Transformation with genomic DNA of the Tn-seq library
mutants served as the positive control as a measure of S. pneumoniae’s competence
during each experiment. The Tn-seq library mutants represented a group of mutants that
had transposon insertions in non-essential genes in S. pneumoniae. The bacteria were
incubated at 37oC with 5% CO2 for 3 hours, and the transformants were selected on blood
agar plates supplemented with appropriate concentration of penicillin or cefepime, 3%
sheep blood, and 20 µg/mL of neomycin after overnight incubation at 37oC and 5% CO2.
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Transformation efficiency was calculated as the ratio of the number of transformant
colonies (CFUs/mL) selected on penicillin- or cefepime-containing plates to the total
number of bacteria on neomycin-containing plates.

In vitro experimental evolution
TIGR4 was used as parental strain in antibiotic evolution experiments. Four
replicate populations were grown in fresh ThyB with an increasing concentration of
penicillin, or vancomycin for antibiotic adaptation populations. Four replicate
populations were serial passaged in ThyB as controls to identify background adaptations
in antibiotic adaptation experiments. When populations were adapted to their antibiotic
environment (ThyB supplemented with 3x MIC of the respective antibiotic), a single
colony was picked from each experiment and checked for its adaptive phenotype by
growth curve experiments. Whole genome sequence was performed for each population
and clones.

In vivo virulence determination
To examine the bacteria’s virulence, the wild-type TIGR4 and the derivative,
transformant mutants were grown in C+Y to logarithmic phase OD620 ~0.8 and frozen as
glycerol stocks at -80oC. Prior to infection, the glycerol stocks were thawed, washed,
resuspended in 1x PBS, and enumerated to confirm the correct CFUs infection dose.
Anesthetized seven-week-old female BALB/c mice from Jackson Laboratory were
infected with the wild type and the mutants via low-volume intranasal instillation of 30
µL containing 1 x 107 CFUs. After the infection, mice were monitored for survival and
disease progression, including lethargy, conjunctivitis, meningitis, pneumonia, and
bacteremia. Blood samples, lungs, and nasal passage were collected at 24 post-infection
via tail-bleeding (5 µL of collected blood was diluted into 1x PBS containing heparin)
and dissection, respectively. Bacterial burden was enumerated by serially diluting into 1x
PBS and plating onto blood agar, and bacterial titers were compared using the nonparametric Mann-Whitney t-test. Mouse survival curves were analyzed using the MantelCox log rank test.

Lung harvest and histology
From each infected mouse, the left lung was collected for enumeration of
bacterial burden, while the right lung was sent to SJCRH histology / pathology
department for evaluation of inflammation severity. Briefly, right lobes were perfused
and fixed with 10% formalin. Sections were stained with hematoxylin-eosin for
evaluation under light microscopy. A scoring system were developed to quantify and
compare histopathology of lungs infected by the recombinants to their respective wildtype strains. Criteria for the scoring system included vascular injury, leukocytes in lungs,
collapsed alveoli, pulmonary edema. The scoring system was graded on severity and
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extent of injuries, ranging from 0 = within normal limits, 1 = minimal (rare or
inconspicuous lesions), 2 = mild (multifocal or small, focal, or widely separated, but
conspicuous lesions), 3 = moderate (multifocal, prominent lesions), 4 = marked
(extensive to coalescing lesions or areas of inflammation with some loss of structure), or
5 = severe (diffuse lesion with effacement of normal structure). Cytokines were also
collected and analyzed for inflammatory signals, including GM-CSF, IL-1β, IL-6, IL-10,
IL-12 (p40), and TNF-α, using the Milliplex® MAP Kit (EMD Millipore Catalog#
MCYTOMAG-70K). Briefly, serum or homogenized lung tissue supernatant was diluted
and assayed against a standard curve using magnetic beads coated with cytokine-specific
antibodies. Streptavidin-phycoerythrin was incubated with samples for detection and
median fluorescence intensity (MFI) was read via Luminex® 200™. MFI output was
normalized based on dilution and standard curve and converted to cytokine concentration
in each sample.

In vivo nasal colonization determination
To enumerate bacterial burden in the nasopharynx of the infected mice at 24
hours post-challenge, the nasal passage composed of nasal cavity, nasopharynx, paranasal
sinus was isolated, mashed on a cell strainer, and washed with 750 µL 1x PBS. The
mixture was then serially diluted and spotted on blood agar plates prior to incubation at
37oC supplemented with 5% CO2 overnight.

BOCILLIN FL-penicillin-binding protein affinity assay
From overnight cultures on blood agar plates, the bacterial strains were inoculated
into C+Y and grown to OD620 ~0.4. Then 1 mL of each bacterial culture was pelleted,
washed with 100 µL of 1x PBS, and resuspended in 100 µL of 1x PBS containing 0.5 µg
of BOCILLIN FL penicillin (ThermoFisher Scientific). After being incubated for 30
minutes at 37oC, the bacteria were pelleted at 6,500 x g for 10 minutes and washed with
100 µL of 1x PBS to remove unbound BOCILLIN FL penicillin. Each bacterial pellet
was resuspended in 100 µL of 1x PBS, TritonX100 0.1%, and 1x complete mini protease
inhibitor tablet before lysis at 37oC for 30 minutes and freezing overnight at -20oC. BCA
assay was performed to determine the concentration of proteins in each pellet. The pellets
were boiled for 3 minutes at 100oC, then 10 µg of protein per sample was resuspended
with 1 x LDS loading buffer without reducing agent and loaded onto an SDS-PAGE gel
(4-12%). Penicillin-binding protein bands were visualized using ChemiDoc with Pro-Q
Emerald 488 settings and quantified using Image Lab software.

Adhesion and invasion assays
A modified version of the adhesion and invasion protocol developed by Orihuela
and colleagues was followed [148]. Briefly, A549 lungs epithelial cells (ATCC) were
cultivated in 24-well-tissuse culture-treated plates (Costar, Corning) until having 90-95%
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confluent monolayers numbering roughly 4 x 105 cells/mL. After being activated at 37oC
with TNF- (10 ng/mL) in F12K media (ATCC) supplemented with 10% FBS and 20
µg/mL gentamicin, cells were washed twice with 1x PBS and then infected with 1 mL of
~107 bacteria at mid-logarithmic phase OD620 ~0.4, which yields the MOI of ~25:1. Once
bacteria and cells were incubated for 30 minutes at 37oC, the supernatant was serially
diluted and plated onto blood agar to determine the number of non-adherent bacteria.
Cells with adhered bacteria were washed twice with 1x PBS and detached with 100 µL of
0.1% Trypsin-ETDA (ThermoFisher) in 1x PBS for 5 minutes at 37oC. Cells were
resuspended in 900 µL 1x PBS. To determine the number of adherent bacteria, the cell
suspension was serially diluted and plated onto blood agar. Ratios of adherent bacteria to
total bacteria number for each strain were calculated. Total bacteria number was
calculated by adding adherent bacteria and non-adherent bacteria. Each bacterial strain
was represented in three biological replicates in independent experiments.
For the invasion assay, A549 cells were seeded, activated, and infected as in the
adhesion assay except the following. After bacterial infection, cells were incubated at
37oC with 5% CO2 for 2 hours and washed twice with 1x PBS. To eliminate extracellular
bacteria, cells were incubated with 1 mL of infection media, which contained F12 media,
1:100 Pen/Strep solution, and 200 µL gentamicin), for 1 hour at 37°C 5% CO2 before
washing 3 times with 1x PBS. Then, 100 µL of 0.1% Trypsin-EDTA in 1x PBS was
added to each well to detach cells, and the suspension was incubated for 5 minutes at
37oC. Cells were lysed by incubating with 200 µL of 0.025% ice cold Triton x100 in
water for 8 minutes at 37oC. Finally, to determine the number of intracellular bacteria,
cells were resuspended completed by pipetting, and 200 µL of the suspension was spread
onto blood agar plates. Ratios of intracellular bacteria to total number of bacteria were
compared those of TIGR4. Total number of bacteria is equal to the sum of intracellular
bacteria and extracellular bacteria, which were determined by plating the supernatant
immediately after the 3-hour incubation post-infection with bacteria. Each bacterial strain
was assayed in three biological replicates conducted in independent experiments.

Macrophage phagocytosis assay
J774A.1 murine macrophages were subcultured in DMEM (Dulbecco’s Modified
Eagle Medium, ThermoFisher) supplemented with FBS (fetal bovine serum, 10% vol/vol,
Sigma), 50 mg/mL streptomycin and 50 units/mL penicillin (Sigma). Once reaching at
70-80% confluent monolayers in 24-well plates, cells were washed 3 times with 1x PBS
and resuspended in DMEM containing 3% bovine serum albumin (BSA, Sigma) without
antibiotics. Then, cells were activated with fresh murine serum prior to infection with 100
µL of bacteria at OD620 ~0.1, which corresponds to a multiplicity of infection of 50
bacteria to 1 macrophage). Cells were incubated with bacteria at 37oC for 30 minutes or 1
hour, and then washed followed by incubation for 1 minute with DMEM containing 100
µg/mL gentamicin. The washing and incubation process was repeated 3 times. Finally,
the macrophages were lysed using 0.025% Triton, serially diluted, and plated onto blood
agar plates to enumerate viable engulfed, intracellular bacteria.
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Time-kill assay
The WT and derivative, transformant, mutant strains were grown in ThyB to early
logarithmic phase OD620 ~0.2. The bacteria were exposed to respective 10x MIC of either
penicillin or cefepime. Bacterial CFUs were tittered and plated onto neomycin-containing
blood agar plates prior to antibiotic exposure and hourly for 4 hours post-exposure.

Genomic DNA extraction
Genomic DNA of the WT and the derivative, transformant strains were extracted
via the aqueous / organic extraction method using phenol chloroform. Briefly, the
bacteria were grown in C+Y to late logarithmic phase at OD620 ~0.6 and were pelleted at
6000 x g for 10 minutes followed by lysis in 1 mL 1x PBS containing 50 µL 10% DOC,
50 µl 10% SDS, and 10 µL of 10 mg/mL Proteinase K (Sigma). The suspension was
incubated until clear (approximately 5 minutes) at 37oC, mixed with 500 µL phenol:
chloroform: isoamyl alcohol (Sigma), transferred to phase-lock tubes (Quantabio), and
centrifuged at maximum speed for the separation of aqueous and organic phases. Then
500 µL chloroform: isoamyl alcohol was added to, mixed with the aqueous phase, and
centrifuged. To precipitate DNA, the aqueous phase was transferred to a new Eppendorf
tube containing 100% ethanol. Precipitated DNA was washed with chilled 70% ethanol,
pelleted, dried, and resuspended in nuclease-free water.

Whole genome sequencing and analysis
Extracted genomic DNA from the recombinants were sent to Hartwell Center for
whole genome sequencing. Sequence libraries were barcoded using the Nextera kit
(Illumina), and run on the Illumina HiSeq2000 platform as previously described [149].
The reads were mapped and compared to the TIGR4 reference genome for analyzing
mutations resulting from recombination events.

Results

Early recombinant pneumococcal strains exhibit MICs comparable to
experimentally-evolved isolates
Table 4-1 displays the minimum inhibitory concentrations of the β-lactam
antibiotics penicillin and cefepime for generated strains, parents, and donor strains used
in this study. Recombinant β-lactam resistant pneumococcal strains were generated via
transformation with genomic DNA (gDNA) from clinical isolates of resistant viridans
group streptococci (VGS). Second- and third-round recombinants, so named because they
are the result of successive transformations of the previous “round” of successful
transformants, were subsequently created by repeating transformation an additional one
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Table 4-1.
MICs of wild-type pneumococcal strains, their derivative,
recombinant mutants, viridans group streptococcal donor strains, and
experimentally-evolved pneumococcal populations
Strain

ID

T4
T4R1P
T4R2P.1
T4R3P.1
T4R2P.2
T4R3P.2
D39
D39R1P
D39R2P
D39R1C
D39R1C
T4 316
T4EV
T4EP
SV2
SV3
SV4
SV5
SV8

T4
T4+SV5
T4+SV5+SV3
T4+SV5+SV3+SV11
T4+SV5+SV8
T4+SV5+SV8+SV4
D39
D39trSV2A Pen
D39Sv2AtrSV5A Pen
D39trSV2A Cefep
D39SV2AtrSV5A Cefep
T4 316
TvO VanR Pop1
TvO PenR Pop1
SV2
SV3
SV4
SV5
SV8

Description
Parent
1st recombinant
2nd recombinant
3rd recombinant
2nd recombinant
3rd recombinant
Parent
1st recombinant
2nd recombinant
1st recombinant
2nd recombinant
Parent
Experimentally-evolved population
Experimentally-evolved population
VGS clinical isolate
VGS clinical isolate
VGS clinical isolate
VGS clinical isolate
VGS clinical isolate
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Penicillin MIC
(µg/mL)
0.008
0.032
0.047
0.19
0.047
0.38
0.008
0.023
0.047
0.023
0.016
0.012
0.023
0.023
0.75
1.5
2
4
>32

or two times, respectively, in the presence of VGS gDNA with colony selection on
penicillin or cefepime blood agar plates. In contrast, β-lactam resistant point mutant
populations were experimentally evolved via in vitro continual passaging of the initial
parent strain T4 316 in sub-inhibitory concentrations of antibiotics. When comparing the
MICs to penicillin of the recombinant isolates versus the experimentally-evolved
populations, first recombinants (T4R1P and D39R1P) possessed similar penicillin
susceptibilities as the experimentally-evolved isolates T4EP and T4EV. Both the
penicillin-evolved pneumococci population T4EP and the vancomycin-evolved
population T4EV were selected as comparators due to comparable increases in penicillin
MIC as the initial recombinant strains. As expected with subsequent transformations,
MICs to penicillin and cefepime increased in the second- and third-round transformation
strains. Though recombinant isolates were screened on single antibiotics (either penicillin
or cefepime), many strains, particularly, the later (second- and third-round) recombinant
series showed decreased susceptibility to both agents, suggesting that chromosomal
recombinations at common β-lactam targets may be involved.

Inter- and intraspecies recombinants exhibited similar transformation efficiencies
gDNA of 20 clinical VGS strains were isolated for use in generating recombinant
β-lactam resistant S. pneumoniae. Of these, the gDNA of ten VGS strains yielded
successful transformants when co-incubated with either wildtype D39 (serotype 2) or
TIGR4 (T4, serotype 4). gDNA from known resistant pneumococcal isolates was also
transformed into the parent strains as comparators. The transformation efficiencies for the
interspecies recombinants varied between 10-6 and 10-8 per 5 µg of gDNA, which was
comparable to the transformation efficiencies of generating intraspecies recombinants
(Figure 4-1 and 4-2). Subsequent transformations using first-round transformants also
did not alter transformation efficiency when generating second- and third-round
recombinants. Overall, our results suggest that for VGS strains whose DNA was readily
uptaken by S. pneumoniae, the transformation efficiency was close to that of intraspecies
recombination under the same conditions. However, the success of DNA uptake and
recombination is likely strain- and condition-dependent.

First recombinant pneumococci are not attenuated in vivo compared to wild-type
strains
In order to compare in vivo fitness and other phenotypic traits between β-lactam
resistant strains, we challenged anesthetized, 7-week-old BALB/c mice with intranasal
inoculums of either recombinant pneumococci or the penicillin and vancomycin
experimentally-evolved populations and monitored survival and enumerated bacterial
burden in the blood 24 hours post-infection (Figure 4-3). Early recombinant
pneumococcal strains – i.e. the first recombinants T4R1P, D39R1P, and D39R1C
exhibited blood titers equivalent or greater to that of the parent strains T4 and D39. A
similar observation was made with regard to overall mouse survival in which early
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Figure 4-1. Transformation efficiencies of parental TIGR4 with genomic DNA of
viridans group streptococci
Transformation efficiency was calculated as the ratio of the number of recombinant CFUs
selected on penicillin-containing blood agar plates to the total number of CFUs. A) First
round transformation efficiencies. B and C) second round transformation efficiencies. D
and E) and third round transformation efficiencies of TIGR4 parental strain. Positive
control transformation efficiencies were generated from Tn-Seq library genomic DNA.
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Figure 4-2. Transformation efficiencies of parental D39 with genomic DNA of
viridans group streptococci
Transformation efficiency was calculated as the ratio of the number of recombinant CFUs
selected on either penicillin or cefepime-containing blood agar plates to the total number
of CFUs. First round transformation efficiencies in D39 on either B) penicillin or C)
cefepime and second round transformation efficiencies screened on D) penicillin or E)
cefepime are displayed for VGS donor gDNA as well as Tn-Seq library gDNA positive
controls. Transformation efficiencies for resistant pneumococcal genomic DNA was also
performed as a comparator.
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Figure 4-3. Blood titers and mouse survival after intranasal challenge with
recombinant versus experimentally-evolved pneumococci
Seven-week old BALB/c mice were intranasally infected with 106 CFUs of either A and
B) TIGR4 and its derived recombinant strains. C and D) D39 and its derived recombinant
strains. E and F) T4 316 and its derived experimentally-evolved populations in groups of
five. Bacterial blood titers were obtained via tail-vein bleed 24 hours post-infection.
Mouse survival was followed out to 10 days post-infection.
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recombinant strains displayed virulence equal to or greater than that of the wildtype
parent strains. In contrast, the experimentally evolved isolates were highly attenuated,
exhibiting significantly lower blood titers compared to the T4 316 (serotype 4) parent
isolate and greatly reduced 10-day mortality. Second and third recombinants in general
also showed attenuated virulence in the mouse model, with the exception of the secondround recombinant D39R2C, which behaved similarly to the first recombinant parent.
Based on our observations, early recombinants do not initially possess attenuated traits in
vivo, and attenuation was not observed until S. pneumoniae underwent further recombination via horizontal gene transfer. Furthermore, the levels of attenuation observed
in the later recombinant pneumococcal strains was comparable to the decreased virulence
seen in mice challenged with the penicillin and vancomycin experimentally-evolved
isolates. These data initially suggest that early recombinants can possess decreased
susceptibility to β-lactam agents without significant defects to in vivo fitness.

In vitro phenotypes of recombinant versus experimentally-evolved pneumococcal
strains were not significant
To further assess the phenotypes of the resistant recombinant strains in
comparison to the experimentally-evolved pneumococcal isolates, strains were incubated
with A549 human alveolar basal epithelial cells to compare strain capacity for invasion
and adhesion (Figures 4-4 A and B). While some changes in the ability of the recombinant strains to adhere to cells were observed, overall results were inconsistent
between any of the tested strains that might explain differences in attenuation seen in vivo
between the second and third recombinants compared to the first recombinant series. For
example, while the second- and third-round recombinants T4R2P.1, T4R3P.1, T4R2P.2,
and T4R3P.2 showed elevated adhesion to alveolar epithelial cells compared to TIGR4,
the same could not be said of the second-round recombinants D39R2P and D39R2C,
which were not significantly different from D39 (Figure 4-4A). Similarly, quantification
of intracellular pneumococcal cells revealed differences inconsistent between
recombinants and the wildtype, suggesting that changes in invasion were not primarily
responsible for fitness differences seen in vivo (Figure 4-4B). Additionally, neither
experimentally-evolved strain showed significantly different adherence compared to T4
316 (Figure 4-4A).
We next assessed whether differences in macrophage phagocytosis existed
between recombinant strains, their parents, and experimentally-evolved isolates. For this,
J774A.1 murine macrophages were co-incubated with respective pneumococcal strains at
an approximate MOI of 50. In comparison with each respective strain’s parent, D39R1C
and T4EV demonstrated significantly higher macrophage phagocytosis, while D39R1P
exhibited significantly lower phagocytosis (Figure 4-4C). All other strains did not
significantly differ from their respective parent, as measured by the proportion of
intracellular S. pneumoniae cells present inside lysed macrophages versus total
pneumococcal cells present overall. The measure of intracellular S. pneumoniae may
indicate a significant alteration in the ability of the pneumococcal cells to survive
intracellularly after phagocytosis and/or the amount/ability of macrophages to ingest the
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Figure 4-4. Adhesion and invasion and macrophage phagocytosis for recombinant
pneumococcal strains versus parental strains and experimentally-evolved
populations
A) Adhesion assays using A549 murine lung epithelial cells were performed to examine
the adhesion of TIGR4 and D39 and derivative first, second, and third recombinant
strains, T4R2P.1, T4R3P.1, T4R2P.2, and T4R3P.2, respectively, and experimentallyevolved strains and their WT T4 316. Adhesion ratio was calculated as the ratio of the
number of adhered CFUs to the total number of CFUs, which was the sum of adherent
and non-adherent CFUs. B) Invasion assays using A549 murine lung epithelial cells were
performed to examine the invasion of TIGR4 and D39 and derivative first and third
recombinant strains, T4R2P.1, T4R3P.1, T4R2P.2, and T4R3P.2, to A549 cells. Invasion
ratio was calculated as the ratio of the number of adhered CFUs to the total number of
CFUs at time of plating. The total bacterial number expressed as CFUs was the sum of
invaded (engulfed) and remaining bacteria in the supernatant. In both the adhesion and
invasion assays, each strain was measured in three biological replicates. C) Enhanced
macrophage phagocytosis observed with D39-derived first recombinant D39R1C and
T4E compared to their parent strains. The recombinants and their respective WT strains
were incubated with activated murine macrophage cells J774A.1 at MOI 50. Macrophage
killing assay were conducted in three biological replicates. The recombinants and
experimentally-evolved. Strains were compared to their respective parent strains using
unpaired t-tests.
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invading pneumococcus. However, here we saw no strong trends of recombination versus
de novo mutation lending to consistent changes in killing by macrophage.
In order to determine alterations in PBP-binding affinity of the recombinant
strains and the experimentally-evolved isolates, BOCILLIN FL, a fluorescent penicillin
derivative, was added to actively dividing bacteria during mid-logarithmic phase, and
whole-cell protein was purified and quantified. A standard concentration of 10 µg was
loaded and run via gel electrophoresis which allowed for the visualization of fluorescent
PBP bands, in which band intensity would correlate with PBP abundance and BOCILLIN
FL-binding affinity. Quantification of band intensity revealed no large changes in PBPbinding between any strain and its parent (Figure 4-5). Overall, many of the recombinant
strains showed very slight decreases in band intensity for many, if not all, of the six
visualized PBPs, perhaps suggesting a slight decrease in the PBPs’ affinity to BOCILLIN
FL compared to the parent strain. However, our data indicate that the differences in
BOCILLIN FL-PBP binding affinities between recombinant strains was also modest, and
therefore not likely wholly responsible for differences in virulence and fitness seen
between recombinant strains.
Initial recombination with resistant determinants to β-lactams, such as penicillin
and cefepime, induced tolerance to those antibiotics
Due to their subtle increases in MICs to penicillin and cefepime, we next sought
to investigate whether the recombinants displayed tolerance phenotypes by examining
their kill kinetics in the presence of antibiotics. The Tupelo strain, a prototypical tolerant
pneumococcal strain, served as a reference strain and positive control for tolerance
experiments [150]. Upon exposure to lethal concentrations of penicillin or cefepime
(respective 10x MIC), both TIGR4-derived and D39-derived third-recombinants
exhibited a more gradual decline in bacterial CFUs than that of the susceptible wild type.
The kill kinetics of the third-round, penicillin-screened recombinants also more closely
resembled that of the tolerant Tupelo strain, indicating that these recombinants displayed
tolerance to otherwise lethal concentrations of the antibiotics (Figure 4-6). In contrast,
the first- and second-round recombinants in TIGR44 and D39 backgrounds as well as the
experimentally-evolved isolates T4EP and T4EV showed tolerance to neither penicillin
nor cefepime (Figure 4-6).

First recombinants resulted in similar bacterial burden in the blood and lungs and
similar nasal colonization as wildtype during murine intranasal infection
Initial experiments testing the recombinants’ virulence in our murine model
indicated that the first-round recombinants in both TIGR4 and D39 backgrounds were not
attenuated in terms of bacterial burden in the bloodstream and mouse survival
(Figure 4-3). To further characterize the effects of early recombination in pneumococcal
pathogenesis, we examined the first compared to the less β-lactam susceptible third
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Figure 4-5. BOCILLIN FL-binding assay in recombinant strains, parental
strains, and experimentally-evolved pneumococci
The A) T4-derived recombinants, B) D39-derived recombinants, and C) the
experimentally-evolved pneumococci were transiently exposed to fluorescent, PBPbinding BOCILLIN FL, and fluorescent band intensity for 6 PBPs were visualized and
quantified. Difference in BOCILLIN FL affinity for PBPs compared to the parent is
expressed as log-fold change in band intensity.
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Figure 4-6. Bacterial time-kill curves with penicillin and cefepime
Half-hour bacterial titers were taken after exposure to 10x MIC of either penicillin for A)
T4-derived strains, B) D39-derived strains, and C) T4 316-derived strains or cefepime for
(D) D39-derived strains and E) T4 316-derived strains. Bacterial growth is represented as
a percentage of the bacterial CFU/mL taken at time=0 prior to addition of antibiotic. The
prototypical tolerant S. pneumoniae strains, Tupelo, and the ∆lytA mutants in T4 and D39
were included as reference strains for tolerance phenotype.
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recombinants’ virulence in different host’s niches, including nasal passages, blood, and
lungs. At 24 hours post-infection, mice infected with TIGR4-derived first recombinants
had relatively equivalent bacterial burden in the blood, nasal passages, and lungs
compared to mice infected with T4 (Figure 4-7). In contrast, mice infected with T4derived third recombinants had significantly lower bacterial burden in the blood and nasal
passages, p<0.001 and p<0.05, respectively. Displaying the same trend although not
statistically significant, mice infected with D39-derived first- and third-round
recombinants had relatively lower bacterial burden in all three host’s niches compared to
mice infected with D39. Compared to the initial virulence experiment, these results
recapitulated that mutations from initial recombination did not diminish S. pneumoniae’s
ability to colonize and invade the host, whereas mutations resulting from subsequent
recombinations, and consequently the further decreased antibiotic susceptibility, may
decrease the bacteria’s virulence.

Pulmonary histopathological studies revealed heightened inflammation in T4derived, but not D39-derived recombinants
With the lung tissues collected at 24 hours post-infection, we examined the signs
of inflammatory response and extent of lung injuries from infection with the recombinant
mutants and their respective wild-type strains, including vasodilation of blood vessels
(arterioles, arteries, veins), neutrophil migration from the bloodstream into the pulmonary
air space, vascular injuries, leukocytes in lungs, collapsed alveoli, and pulmonary edema.
Cumulative pathological scoring of the right lobar sections of the five mice in each
infected group revealed slightly higher severity of interstitial inflammation, alveolar
involvement, and presence of alveolar neutrophils in T4R1P (25, 36, and 40,
respectively) and T4R3P.1 (32, 28, and 34, respectively) compared to T4 (12, 21, and 20,
respectively). By contrast, the D39-derivative recombinants D39R1P and D39R2P did
not have subjectively different scoring compared to D39. Heat-killed versions of T4,
T4R1P, D39, and D39R1P completely lacked any evidence of infection or inflammation,
suggesting that dead cells and cell fragments were not responsible for damage in the lung
(Figure 4-8).

Inflammatory cytokine profiling revealed no major differences in blood or lung
tissue after intranasal infection
During acute inflammation of lung tissues caused by pneumococcal infection,
neutrophils that infiltrate the lungs and migrate into the pulmonary airspace induce the
expression of regulatory inflammatory cytokines, such as GM-CSF, IL-1β, IL-6, IL-10,
IL-12 (p40), and TNF-α [151]. There were few significant differences in the expression
of cytokines responsible for the acute inflammatory phase collected and analyzed from
mice infected with first or third recombinants compared to their parental strains
(Figure 4-9). Indeed, only expression of IL-6 and TNF-α in the serum of T4R3P.1infected mice compared to those of T4 infected mice were statistically decreased
(p=0.0079). Consistent with the pulmonary histopathological findings, most differences
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Figure 4-7. Bacterial burden in the blood, lungs, and nose 24-hours postintranasal challenge
Pneumococcal titers from either (A) chest cavity blood, (B) lung tissue, or (C) nasal
passages were obtained in each case for T4 or D39, their respective first recombinants,
and the last recombinant exhibiting the highest MIC (T4R3P.1 and D39R1P,
respectively). Titers were obtained 24 hours after intranasal infection with each
pneumococcal strain. N=5 mice per infected group.
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Figure 4-8. Pulmonary histopathology of murine lungs infected with recombinant
mutants vs. the respective wildtype strains, TIGR4 or D39
Representative images of right lobar sections 24 hours post-infection are shown at 10X
magnification for A) heat-killed T4, B) T4, C) heat-killed D39, D) D39, E) heat-killed
T4R1P, F) T4R1P, G) heat-killed D39R1P, H) D39R1P, I) T4R3P.1, and J) D39R2P
strains used in the respective infected mice (n=5 for non-heat-killed strains and n=3 for
heat-killed strains).
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Figure 4-9. Cytokine profiles in collected serum and lung tissue in a murine
intranasal infection model 24 hours post-infection
Concentrations in either the serum or lung tissue of infected mice for A) GM-CSF, B) IL1β, C) IL-6, D) IL-10, E) IL-12 (p40), and F) TNF-α are shown here for T4, D39 and
recombinant pneumococcal strains T4R1P, T4R3P.1, D39R1P, and D39R2P as well as
their heat-killed counterparts. Results are based on five mice (biological replicates) per
non-heat-killed strain with serum and lung samples run in technical duplicate. Results for
heat-killed strains were done in biological triplicates. **p-values ≤ 0.01.
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in cytokines induced by recombinants compared to their parent strains were slight.
Overall, the degree of inflammation and inflammatory markers as a result of infection
with recombinant strains closely resembled that of the parent strains, indicating that the
recombinants’ abilities to cause inflammation and tissue injury was not attenuated.

Recombinant pneumococcal isolates showed large, regional genomic changes
When examining their genome sequence against their parent strains, recombinant
pneumococcal isolates showed several large SNP-rich regions, likely indicating sections
of the genome where recombination with the exogenous VGS DNA took place
(Figure 4-10A and B). For example, in the first recombinant series T4R1P, a segment of
roughly 4 kb containing multiple genes, including the β-lactam target PBP2X, is densely
populated with SNPs. Presumably this region underwent recombination with the VGS
DNA from isolate SV5, in which antibiotic pressure selected for recombinant PBP2X. As
one might expect, recombinant PBP2X was conserved in successive recombinations
screened on penicillin, and accumulated additional SNPs occurring after each additional
transformation. Indeed, changes in the ~300,000 bp region containing the PBP2X locus
was prominent and conserved in every recombinant isolate sequenced (Figures 4-10A
and B). The third series recombinants T4R3P.1 and T4R3P.2, both derived from T4R1P
and possessing recombinant PBP2X, also both integrated recombinant changes in
PBP2B, despite the fact that the donor DNA used to generate the recombinants was
sourced from two different VGS isolates.
Similar broad changes to PBP2X and PBP2B were seen in D39 recombinants.
The first recombinant screened on cefepime, D39R1C, for example, possessed several
mutations in PBP2X after a single transformation spanning a roughly 260 bp section of
the gene. A much larger recombination occurred after a successive transformation with
SV5 VGS gDNA as the changes to the PBP2X gene in D39R2C spanned more than 2 kb
(Figure 4-10C and D). By contrast, D39R1P and D39R2P were first and second
recombinants, respectively, utilizing the same donor gDNA as D39R1C and D39R2C,
except screened using penicillin. Here, an initial large 2kb recombination within PBP2X
was seen in the first recombinant, while a >1kb segment in PBP2B was changed after retransformation (Figure 4-10C and D). Thus, while the genes targeted during
recombination under β-lactam selective pressure were often the same, the magnitude and
scope of these changes could vary considerably.
Additionally, we observed variable changes in non-PBP regions of the genome for
each recombinant. Both isolated polymorphisms and SNP-heavy regions of
recombination were present in all recombinant series. Notably, T4R1P and all of its
derivative strains possessed a recombinant MurM gene, involved in the production of
pneumococcal branched-stem peptides and PBP-mediated β-lactam resistance [152].
Also within this series of recombinant isolates was the presence of a 5 kb recombinatorial
region encompassing, among others, genes encoding LuxS, which helps in the regulation
of virulence and fitness genes during biofilm formation, ClpB, a heat-shock and stress-
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Figure 4-10. Genome mapping and frequency of SNPs in recombinant vs. parental
strain
Maps of genomic changes present in A) the T4 parent and recombinant series T4R1P,
T4R2P.1, and T4R3P.1 and B) the T4 parent and recombinant series T4R1P, T4R2P.2,
and T4R3P.3 compared to the reference strain TIGR4 (NCBI Reference Sequence:
NC_003028.3) as well as C) the D39 parent and recombinant series D39R1C and
D39R2C and D) the D39 parent and recombinant series D39R1P and D39R2P compared
to the reference strain D39 (NCBI Reference Sequence: NC_008533.2). Strains are
denoted by differently colored rings. SNPs are illustrated by darkened lines with
frequency denoted by length of the line across the width of the ring (i.e. SNPs conserved
within 100% of the sequenced population span the width of each respective ring).
Position along the pneumococcal genome is circumscribed on the outer edge of each
figure.
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response protein, and DexB, a highly conserved glucosidase known to flank one side of
the pneumococcal capsular polysaccharide locus. No other PBP-associated genes were
localized in this region, suggesting that one of more of these gene changes may be
advantageous for the pneumococcal cell with regard to β-lactam exposure. These changes
come largely in contrast with the experimentally-evolved isolates, which possessed few
conserved (100% of the sequenced population) point mutations. Decreased susceptibility
for T4EP likely stems from a single Y586S amino acid change in PBP2X. Other changes
included single point mutations in the cell wall biosynthesis component, MurE, the
capsular polysaccharide biosynthesis gene, Cps4E, a DHH subfamily 1 protein, and an
ATP-binding cassette transporter. Likewise, T4EV possessed two conserved mutations,
again in Cps4E and in the cell division-associated gene FtsW. In both of these isolates,
many of these genes have been linked either as resistance determinants or virulence
factors in S. pneumoniae [153-155]. However, it is unknown whether these genomic
changes would be solely responsible for the in vivo attenuation observed and increased
MICs to the β-lactams.

Discussion
In this study, we have generated recombinant pneumococcal isolates with
decreasing susceptibilities to β-lactam antibiotics. In turn, these isolates were tested and
shown to have variable fitness in intranasal mouse infection models, where bacterial
blood and lung tissue titers, nasal colonization, and overall lethality tended to be
inversely related with serial recombination and increased MIC. The in vitro
experimentally-evolved pneumococcal isolates similarly demonstrated in vivo attenuation
to an extent similar to the second- and third-round recombinants. However, all first-round
recombinants exhibited in vivo fitness similar to the wild-type parent strains despite
slightly elevated MICs to the β-lactams.
We identified few significant changes to virulence phenotypes in the recombinant
isolates compared to wildtype. Furthermore, many differences measured in vitro did not
appear to translate in vivo. For example, the second and third recombinants, T4R2P.1,
T4R2P.2, T4R3P.1, and T4R3P.2 all exhibited increased adhesion to A549 cells in vitro,
which suggests possible advantages to colonization. However, nasal colonization titers
with T4R3P.1 in mice actually showed decreased colonization 24 hours post-infection
compared to T4 316. Similarly, the scoring of lung histology comparing the resistant
recombinant pneumococcal strains suggested that there was a subjective increase in
inflammation with recombinant S. pneumoniae strains compared to wildtype, despite lack
of significance in inflammatory cytokine profiling of the lungs and blood. Consistent
with the alterations in PBP2X found in all resistant pneumococcal recombinants, a slight
decrease in BOCILLIN FL-binding affinity was observed for PBP2X in all recombinants
compared to the parent isolate. Our results appear to indicate that changes to any one
virulence trait studied here were relatively minor and that perhaps the cumulative effect
of these deficits results in the overall attenuation seen in vivo with some of the
recombinant strains.
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While the evolution of antibiotic resistance is very often accompanied by a
tradeoff in fitness, growth, and/or virulence, the underlying cost associated with
resistance development is highly variable and dependent on the genetic mechanisms
driving resistance [56, 146]. Altered β-lactam susceptibility has been tied to differences
in virulence and transmission in pneumococcal isolates [156, 157] and specifically the
acquisition of resistant PBP alleles has been shown to come at the expense of fitness
determinants in competitive nasal colonization models [145]. Our findings demonstrated
that resistant strains evolved via different mechanisms, i.e. horizonal transfer versus de
novo mutation, can have rather dissimilar in vivo fitness despite exhibiting similar
susceptibilities. The attenuation to invasion without any significant change in
colonization seen in vivo with the de novo mutant strains indicates that resistance
acquired by horizontal transfer may be preferable from an evolutionary standpoint.
Mechanistically, it is possible that horizontal transfer allows for a hugely diverse
exchange of genetic material among isolates, which under drug pressure might engender
selection for low-cost resistance traits or accompanying compensatory genetic changes.
In all cases of β-lactam induced resistance within the isolates we examined, we
saw changes to the penicillin-binding protein PBP2X, and in many cases, especially in
later recombinants, alterations in PBP2B. Some mutations in PBP1A and PBP2X have
been identified as compensatory mutations that may restore fitness to S. pneumoniae,
stabilizing resistance mutations by allowing their dissemination in the face of competition
with wildtype strains [158]. Within our isolates, upwards of 200 amino acid changes
were found in PBP2X of many of the recombinant series, which contrasts with the
experimentally evolved penicillin-resistant T4EP population, possessing only a single
amino acid substitution in the central transpeptidase domain of PBP2X. Despite the
relative lack of PBP changes, T4EP was greatly attenuated in vivo. The recombinant
pneumococcal isolates, on the other hand, began showing attenuated in vivo
characteristics only after larger increases in MIC in the later recombinations,
unsurprisingly when many of the isolates began showing large changes in PBP2B. Thus,
it appears that the changes to PBP2X in the first recombinant isolates had a net-neutral or
net-minimal cost to fitness in vivo, with possible compensatory changes conferred by
substitutions within PBP2X itself, or from other alterations in the recombinant genome.
Several large recombination regions in resistant isolates also involved genes not directly
known to be associated with β-lactam resistance. For example, T4R1P possessed
genomic recombinations involving LuxA, DexB, and ClpB, which are themselves not
known to be directly involved in β-lactam resistance. These alterations, and in particular
the changes that occurred in the tolerant third recombinant strains, may be of interest for
investigating determinants and tolerance and resistance. However, the broad scale of
change seen within many of these genes poses a significant hurdle to identifying the
contributions of any one individual mutation.
Here we have shown evidence that S. pneumoniae’s innate competence provides
for greater genetic diversification and adaptability compared to de novo mutation. This
advantage has important implications not only for the pneumococcus, but also nonpneumococcal streptococci. In part, this flexibility afforded by genetic recombination via
horizontal gene transfer may explain the lack of β-lactam resistance observed in non-
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competent species of streptococcus, such a S. pyogenes [159]. A reliance on de novo
mutation without accompanying plasticity to allow compensatory changes could explain
the constraints in PBP variability seen in S. pyogenes, for example [160]. By contrast, the
genomic plasticity of S. pneumoniae allows greater diversity, selection, and adaptation in
low-fitness environments [161, 162], such as in the presence of antimicrobial agents.
Based on this and our current data, we propose that the genetic variability via
recombination grants a considerable advantage, not only in developing antibiotic
resistance, but also in simultaneous adaptation to the host-response.

73

CHAPTER 5. TOLERANCE INDUCED BY DISRUPTION IN RNA
DEGRADATION EVADES FITNESS TRADEOFFS, WHILE POTENTIALLY
FACILIATING THE DEVELOPMENT OF ANTIBIOTIC RESISTANCE

Introduction
Streptococcus pneumoniae is a leading cause of mild to severe infections,
especially in the pediatric and geriatric populations [3], and the burden of pneumococcal
disease is further complicated by the rampant spread of antibiotic resistance worldwide.
Currently, a variety of routine screening methods almost exclusively detects antibiotic
resistance in clinical isolates [163], while overlooking other bacterial phenomena that can
result in treatment failure, such as antibiotic tolerance [164]. Despite these obstacles,
tolerant strains are consistently identified amongst both Gram-positive and Gramnegative clinical isolates.
Antibiotic tolerance was first described in S. pneumoniae in 1970 [165]. The
capacity of a bacterium to evade the bactericidal action of antibiotics without discernible
shifts in resistance is known as antibiotic tolerance [44]. Initially described over 40 years
ago, antibiotic tolerance results in the bacterial population having much reduced
susceptibility to the lethal action of antibiotics. While antibiotic resistance is readily
measured by alterations in minimum inhibitory concentration, tolerance typically
manifests as delayed kill kinetics in the absence of discernible shifts in MIC. Identifying
antibiotic tolerant strains requires measurement of antibiotic kill kinetics, which entails
periodic sampling of bacterial counts in antibiotic-containing media to measure reduction
in bacteria over time, thereby making their classification much more laborious and
challenging. Whereas the basis for antibiotic resistance is well understood, the
mechanisms underlying antibiotic tolerance remain markedly less characterized despite
recent studies that have provided insight into the various underlying mechanisms. Often
overshadowed by the prominence of antibiotic resistance, antibiotic tolerance can result
in antibiotic treatment failure and recalcitrant bacterial infections, and it is thought to be a
potential avenue for the subsequent development of high-level resistance [97, 166, 167].
Antibiotic tolerance is classified into phenotypic tolerance and genotypic
tolerance. Under environmental changes such as starvation stress, lowering pH, or
presence of autolytic enzymes’ inhibitors, almost all bacteria become resistant to cell wall
inhibitors, i.e. beta-lactams [168, 169]. In such nutrients deprived conditions, the bacteria
can activate the stringent response by inhibiting essential cellular processes, such as the
synthesis of cell wall peptidoglycan, proteins, and DNA during replication [170]. As nongrowing or slow-growing bacteria decrease their cellular activities, for example cell wall
synthesis, they exhibit reduced death and lysis and evade bactericidal action of betalactams [169].
Genotypic tolerance results from genetic mutations involved in the lytic pathway.
In S. pneumoniae, absence or inactivity of the autolysin lytA leads to loss of lysis and
reduced killing [165]. It was shown that this reduced killing was due to inhibition of
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autolytic enzymes, such as the major autolysin LytA in S. pneumoniae [171, 172]. LytA
is a cell wall hydrolase that is constitutively expressed during the entire cell cycle but
induces lysis only during stationary phase [165]. Tolerant pneumococcal isolates showed
lytic defects [173] and mutations disrupting autolytic pathway, including the twocomponent regulatory system (VncS-R), the heat-shock protein (ClpC), the zincmetalloprotease (ZmpB), and the ABC transporters (Psa and Pst) [174-178].
Infection resolution via bacterial clearance does not rely solely on antibiotics as
the immune system is also required to completely eradicate an infection. Therefore,
having an impaired immune system increases not only those individuals’ susceptibility to
infection but also their chance of developing chronic infections. Without a fully
functional immune system, bacterial clearance in the immunocompromised host relies on
the efficacy of antibacterial treatment to successfully eradicate the infection. In many
cases, conventional dosing of first-line antibiotics is appropriate for treating bacterial
infections in immunocompromised patients. However, in some cases, infections causing
mild or moderate disease in immunocompetent patients can be difficult to treat or even
fatal in an immunocompromised host. Adding to the difficulty of determining the correct
treatment for immunocompromised patients, in vitro antibacterial susceptibility tests do
not always accurately predict in vivo treatment outcome because the dynamics between
the pathogen, infection, and antibiotics are considered. This is of particular importance to
high-risk individuals with impaired immune function as successful treatment does not
have the added benefit of synergistic clearance by the host immune system thus allowing
for pathogen outgrowth following cessation of antibiotic exposure. While such
mechanisms of evading antibiotic eradication are likely to be operative regardless of host
immune status, these high-risk populations remain of a particularly heightened concern.
In this study, we aimed to identify mutations and study mechanisms that enable S.
pneumoniae to overcome antibiotic treatment in our in vivo model of the evolutionary
pathway of antibiotic resistance and resultant treatment failure in murine hosts with
different immune status. We focused on exploring disruption of RNA degradation as a
mechanism underlying antibiotic tolerance in S. pneumoniae that could potentially
accelerate the emergence and spread of antibiotic resistance. RNA degradation has only
been studied extensively in E. coli, B. subtilis, and S. aureus. One of the essential
ribonucleases in bacterial RNA degradosome complex is RNAse Y. It is a degradosome
scaffold protein for mRNA degradosome assembly composed of RNA helicase CshA and
PNPase [179-184]. Within the RNA degradosome, RNase Y interacts with other
components, such as CshA, which is a RNA helicase: ATP-dependent RNA helicase.
Previous studies indicated a surprising association between RNAses and antibiotic
resistance and tolerance. M. tuberculosis clinical isolates resistant to isoniazid harbored
nonsense and insertion and/or deletion mutations in RNase J [185, 186]. In addition, M.
leprae clinical isolates also contained polymorphisms in RNase D and RNase J that were
favored during antibiotic stress [187]. However, the role of RNA degradation in antibiotic
resistance or tolerance has not been explored. Understanding how RNA degradation
plays a role in the conferring antibiotic tolerance, thereby acting as a precursor in the
development of antibiotic resistance will provide insight into curtailing antibiotic
resistance in S. pneumoniae.
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Methods
Growth conditions
The wild-type S. pneumoniae TIGR4 and the deletion mutants were grown on
tryptic soy agar (TSA, EMD Chemicals) supplemented with 3% of defibrinated sheep
blood and 20 µg/mL of neomycin, in Todd Hewitt Broth (ThyB), or in semi-defined
media (C+Y) [188]. S. pneumoniae produces neomycin, and is thus resistant to the
antibiotic [189]. Neomycin was added to blood agar plates to prevent contamination of
other bacterial species. Bacteria from frozen stocks were inoculated onto blood agar
plates and incubated overnight at 37oC supplemented with 5% CO2. Then, the bacteria
from the blood agar plates were inoculated into liquid cultures and incubated at 37oC
supplemented with 5% CO2.

Mutant generation
Deletion mutants (∆sp_1739, ∆sp_1790, and ∆sp_1739 ∆sp_1790) in TIGR4 316
background were generated via overlap extension PCR [190]. Briefly, 1 kb upstream and
downstream regions of the target gene were amplified via PCR using the following
[SP_1739 up Fwd, SP_1739 up ERM rvs, SP_1739 down ERM fwd, SP_1739 down rvs,
SP_1790 Up Fwd, SP_1790 up SPEC Rvs, SP_1790 down SPEC Fwd, SP_1790 down
Rvs. The upstream and downstream regions were then spliced with an erythromycin- or a
spectinomycin-resistance cassette. The final PCR product was transformed into TIGR4
316 at OD~0.07 to 0.1 with competence-stimulating peptide 2 (CSP-2), and the knockout
mutants ∆sp_1739 and ∆sp_1790 were selected on blood agar plates containing either 1
µg/mL erythromycin or 200 µg/mL spectinomycin, respectively. For the double knockout
mutant ∆sp_1739 ∆sp_1790, deletion of ∆sp_1790 was performed in the ∆sp_1790
background. To confirm the deletion mutants, PCR was conducted using the following
primers to verify the presence of the antibiotic cassette and absence of the targeted gene.
Primers used and strains generated are listed in Table 5-1.

Transformation
TIGR4 and the knockout mutants were grown in C+Y media to OD620~0.07 to 0.1
before they were exposed to fluoroquinolone resistance determinants and competence
stimulating peptide 2 or 1 (CSP-1 or 2). Fluoroquinolone resistance determinants
contained 5 µg of 2 kb PCR fragments encoding either S79Y in topoisomerase IV parC
or S81F in gyrA or 5 µg of genomic DNA of fluoroquinolone resistant S. pneumoniae or
Viridans clinical isolates. The transformation mixture was incubated for 3 hours at 37oC
supplemented with 5% CO2. To select for transformants, 100 to 200 µL of the
transformation mixture were spread on blood agar plates supplemented with 1 to 2x MIC
of ciprofloxacin or levofloxacin. The plates were incubated overnight at 37oC and 5%
CO2. Transformation efficiency was calculated as the ratio of CFU/mL of the
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Table 5-1.

Strains and primers used in this study

Strains/Primers
TIGR4 316
∆sp_1739
∆sp_1790
∆sp_1739∆sp_1790
sp_1739 up Fwd
sp_1739 up ERM rvs
sp_1739 down ERM
fwd
sp_1739 down rvs
sp_1790 Up Fwd
sp_1790 up SPEC Rvs
sp_1790 down SPEC
Fwd
sp_1790 down Rvs

Description/Sequence
Wild-type, pathogenic S. pneumoniae, serotype 4, from Tim
van Opijnen laboratory at Boston College
RNAse Y knockout
RNA helicase knockout
RNAse Y & RNA helicase double knockout
CTTCGATACGGCGACGCAC
GAGTCGCTTTTGTAAATTTGGATAAGAAAGAGCAG
TTGAAAAATTACTG
GTTTGCTTCTAAGTCTTATTTCCGATTTCCATGTTTT
TACCTCATTTTATTG
GAACCTTGGGATGCTATGACCC
GGCATAGCGCTTTTACCTCCTG
GTATTCACGAACGAAAATCGATAGCAGTCCTTTCTA
ACGTGGATTTG
GAAAACAATAAACCCTTGCATATGAATCCTTTTCAA
AAAATTGCACTTTCC
GTCCTTACTATGACTTAGCTAGACAAC
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transformants grown on ciprofloxacin- or levofloxacin-containing plates to the total
number of bacteria.

Genomic DNA extraction
The aqueous / organic extraction method using phenol chloroform was conducted
to extract genomic DNA for transformation and whole genome sequencing. TIGR4 and
the knockout mutants were grown in ThyB to late logarithmic phase at OD620 ~0.6 and
were pelleted at 6000 x g for 10 minutes followed. Bacterial pellets were resuspended in
1 mL 1x PBS containing 50 µL 10% DOC, 50 µl 10% SDS, and 10 µL of 10mg/mL
Proteinase K (Sigma). The resuspended mixture was incubated for lysis until clear
(approximately 5 minutes) at 37oC, mixed with 500 µL phenol: chloroform: isoamyl
alcohol (Sigma), transferred to phase-lock tubes (Quantabio), and centrifuged at
maximum speed for the separation of aqueous and organic phases. The aqueous phase
was mixed with 500 µL chloroform: isoamyl alcohol and centrifuged for 5 minutes at
maximum speed. To precipitate genomic DNA, the aqueous phase was transferred to a
new Eppendorf tube containing 100% ethanol. Finally, precipitated DNA was washed
with ice cold 70% ethanol, pelleted, air dried at room temperature, and resuspended in
nuclease-free water.

In vivo passaging
For this study, we modeled the evolution of fluoroquinolone resistance in vivo
with different clinically relevant antibiotics, such as levofloxacin, cefepime, and
linezolid. Three groups of 7-week-old immunocompetent BALB/c mice were intranasally
instilled with 100 µL containing 106 CFUs of TIGR4. Six hours post-infection, mice were
intraperitoneally administered a sublethal dose of the antibiotic. Initial dosages of each
antibiotic: 100 µL of levofloxacin (25 mg/kg), cefepime (1 mg/kg], vancomycin (0.25
mg/kg) was determined in preliminary studies. The initial dosages eliminated 90% to
99% of the bacterial population and were selected to impose sufficient antibiotic pressure
while not completely eradicating the entire bacterial population (data not shown). After
15 passages, the antibiotic dosage was increased to 2x in each subsequent passage.
Twelve hours post-antibiotic treatment, lungs and blood from chest cavity of infected
mice were harvested. To collect bacteria from the infected lungs, the lungs were
homogenized and centrifuged at 300 x g for 5 minutes. The resultant supernatant was
spread plated on blood agar plates for 12 hours, and frozen in aliquots containing
glycerol. The blood was mixed with 1x PBS containing heparin or EDTA and serially
diluted before spotted on blood agar plates to enumerate bacterial burden after each
passage. Bacteria collected from each passage was frozen using 80% glycerol in
triplicates. For subsequent passage, frozen bacterial aliquots from previous passage of
each respective lineage served as the inoculum to infect the next group of mice. The other
aliquots were used for genomic DNA extraction and whole genome sequencing.
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MIC determination
To measure the MIC of TIGR4 316 and the knockout mutants, bacteria were
grown on blood agar plates overnight at 37oC with 5% CO2. The bacteria grown
overnight were used to inoculate into ThyB and incubated at 37oC with 5% CO2 until
they grew to mid-logarithmic phase at OD620 ~0.4. Then, 100 µL of the bacterial culture
were spread plated on blood agar plates. An E-test strip (bioMerieux) containing
increasing concentrations of an antibiotic was carefully placed onto the center of the
plates, which were then incubated overnight at 37oC with 5% CO2. MIC (µg/mL) of each
strain was determined at the concentration where the symmetrical inhibition ellipse edge
intersects the E-test strips on the plate.

In vitro growth curves
The wild-type TIGR4 and mutants were grown overnight on blood agar plates and
diluted 1:100 in C+Y in triplicates. Bacterial growth was measured as OD620 every 30
minutes by a microplate reader.

Time-kill curves
Kill curves were conducted to examine whether the experimentally-evolved
isolates and the knockout mutants displayed tolerance phenotype to different classes of
antibiotics. TIGR4 and the knockout mutants were grown in ThyB at 37oC supplemented
with 5% CO2 until reaching mid-logarithmic phase at OD620 ~0.2. Bacteria were exposed
to increasing concentrations of different classes of antibiotics, ranging from TIGR4’s 1x
to 4x MIC, for 4 hours. Hourly after antibiotic exposure, bacteria were serially diluted
and spotted on blood agar plates, which were incubated overnight at 37oC and 5% CO2.

Whole genome sequencing
Sequence libraries were prepared according to Illumina HiSeq protocol. To
identify mutations that rose during in vivo passaging, the reads were assembled using
Breseq and compared to the TIGR4 reference genome (AE005672.3).

Virulence and competitive index experiments
For the bacterial virulence study, TIGR4 and the and the mutants were grown in
C+Y to logarithmic phase OD620 ~0.8 and frozen in glycerol stocks at -80oC. Bacteria in
each glycerol stock were enumerated. Immediately before infecting the mice, the glycerol
stocks were thawed, washed, resuspended in 1x PBS, and diluted for appropriate
infecting inoculum concentration. Anesthetized seven-week-old female BALB/c mice
from Jackson Laboratory were infected with the TIGR4 or the mutants via low-volume
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intranasal instillation of 30 µL containing 1 x 107 CFUs. Mice were monitored for disease
progression, including lethargy, conjunctivitis, meningitis, pneumonia, and bacteremia
post-infection. Blood samples, lungs, and nasal passage were collected at 24 postinfection via tail-bleeding (5 µL of collected blood was diluted into 1x PBS containing
heparin) and dissection, respectively. For the competitive index experiment, TIGR4 and
the ∆sp_1739 mutant were equally mixed in the infection inoculum. Seven-week-old
anesthetized BALB/c mice were intranasally instilled 100 µL of the inoculum containing
1 x 106 CFUs. Sixteen hours post-infection, the mice were peritoneally administered
levofloxacin, vancomycin, or cefepime. Blood and lungs were collected at 6 hours posttreatment. Bacterial burden was enumerated by serially diluting into 1x PBS and plating
onto blood agar, and bacterial titers were compared using the non-parametric MannWhitney t-test. Mouse survival curves were analyzed using the Kaplan Meier survival
curves and Mantel-Cox log rank test.

Antibiotic treatment experiment
To ascertain the effect of disruption in RNA degradation on antibiotic efficacy,
seven-week-old anesthetized BALB/c mice were intraperitoneally infected with 100 µL
containing 105 CFU/mL of either TIGR4 or the knockout mutants. Mice were monitored
closely for signs of infection. Sixteen-hour post-infection, blood was extracted via tail
bleeding to enumerate bacterial burden prior to antibiotic treatment. Mice were then
intraperitoneally administered 100 µL of levofloxacin (25 mg/kg), cefepime (1 mg/kg), or
(0.25 mg/kg) vancomycin. Two hours after antibiotic treatment, blood was extracted via
tail bleeding every 2 hours up to 6 hours. Pre- and post-treatment bacterial burden in each
mouse in either TIGR4-infected or the mutant-infected group was compared using
Wilcoxon matched-pairs signed rank test. Kaplan-Meier survival curves were compared
using the log rank test.

Ethics statement
All experiments involving animals were performed with prior approval of and in
accordance with guidelines of the St. Jude Institutional Animal Care and Use Committee.
The St. Jude laboratory animal facilities are fully accredited by the American Association
for Accreditation of Laboratory Animal Care. Laboratory animals are maintained in
accordance with the applicable portions of the Animal Welfare Act and the guidelines
prescribed in Guide for the Care and Use of Laboratory Animals.
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Results

Sp_1739 served as a mutational hot spots for point mutations during pressure by
multiple antibiotics and different immune states during in vivo passaging
For this study, we developed an in vivo serial passaging model to investigate
underlying mechanism(s) leading to the development of antibiotic resistance in both
immunocompetent and immunocompromised mice. We completed almost 30 rounds of
passaging with a variety of clinically relevant antibiotics. Escalating dosages of
antibiotics did not eradicate bacterial burden during the infection, resulting in treatment
failure (Figure 5-1); however, MICs of the experimentally-evolved isolates were
comparable to that of the wild type (data not shown). Without a marked increase in MICs
of the experimentally-evolved isolates, those isolates were predicted to display tolerance
against the antibiotics to overcome antibiotic killing. Indeed, the isolates that underwent
in vivo passaging with levofloxacin displayed reduced kill kinetics during time-kill
curves with levofloxacin (Figure 5-2). Time-kill curves of the experimentally-evolved
isolates with other antibiotics will be conducted in the near future to determine if the
isolates display cross tolerance to other classes of antibiotics.
We next analyzed the whole genome sequences of the experimentally-evolved
isolates to identify mutation(s) that arose after each round of passaging and likely
contributed to conferring tolerance. Currently, only whole genome sequencing results of
experimentally-evolved isolates under cefepime, linezolid, and levofloxacin pressure
were available for analysis. The whole genome sequence of each evolved isolate was
compared to that of the parental TIGR4. We discovered that in multiple independent
murine lineages under the pressure of those different antibiotics, there were numerous
missense and nonsense mutations along the rny gene (sp_1739) or RNAse Y
(Tables 5-2). The mutations started to arise and remained fixated in the population. There
were also a few mutations in other ribonucleases J, ribonuclease HIII, and ribonuclease
R. Intriguingly, those mutations were clustered in the genes responsible for RNA
degradation.

Deletion of sp_1739 does not decrease antibiotic susceptibility compared to the wildtype TIGR4
We previously observed that the RNAse Y gene served as the mutational hotspot
during in vivo passaging with different classes of antibiotics. Multiple mutations
occurring along the rny gene likely disrupted RNA degradation. To determine whether
disruption of RNA degradation affects antibiotic susceptibility of S. pneumoniae, we
generated deletion mutants of rny (sp_1739) and a putative RNA helicase cshA
(sp_1790), which are expectedly major components of the RNA degradosome complex of
S. pneumoniae. Previous work demonstrated that RNAse Y is responsible for the
degradation of a significant amount of mRNA transcripts in B. subtilis. Depletion of
RNAse Y resulted in remarkable accumulation of those transcripts [183].

81

Figure 5-1. In vivo passaging of TIGR4 with different antibiotics and host immune status
A) Cefepime, neutrophil-depleted. B) Cefepime, macrophage-depleted. C) Cefepime, non-depleted. D) Levofloxacin, neutrophildepleted. E) Levofloxacin, macrophage-depleted. F) Levofloxacin, non-depleted. G) Linezolid , neutrophil-depleted. H) Linezolid,
macrophage-depleted. I) Linezolid, non-depleted.
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Figure 5-2. Experimentally-evolved isolates of S. pneumoniae exhibited tolerant
phenotype to levofloxacin
A and B) Kill curves conducted with 1x MIC and 2x MIC of levofloxacin,
respectively.T4 316 (blue) is the wild type. T4 316 L1-L3, G29, Nd (red) represent 3
independent evolved lineages in immunocompetent mice.

Table 5-2.
Antibiotic
Cefepime
Levofloxacin
Linezolid

Summary of mutation occurrence in cefepime in vivo passaging
Macrophage-depleted
L1
L2
L3

✓
✓

✓
✓

Neutrophil-depleted
L1
L2
L3

✓
✓
✓

✓
✓
✓

*L1, 2, and 3 denotes lineage 1, 2, and 3.
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✓
✓
✓

L1

✓
✓

Non-depleted
L2
L3

✓
✓
✓

We also generated a double knockout of both sp_1739 and sp_1790 to maximally
disassemble the RNA degradosome complex. Using E-test strips, we measured the
mutants’ MIC of levofloxacin, cefepime, and linezolid, the antibiotics to which the
experimentally-evolved isolates were exposed during in vivo passaging. Surprisingly,
levofloxacin, cefepime, and linezolid MICs of the single and double knockout mutants
were similar to that of the wild type (Table 5-3). No change in the mutants’ MIC to those
antibiotics suggest that the resulting disruption in RNA degradation did not alter their
susceptibility to the antibiotics and did not induce antibiotic resistance in S. pneumoniae.

Disruption in RNA degradation induced tolerance in S. pneumoniae to multiple
classes of clinically relevant antibiotics
Since the single and double knockout mutants were not resistant to the antibiotics,
we next searched for other bacterial survival strategies that enabled the bacteria to
overcome antibiotic treatment. One of the bacterial survival strategies is tolerance.
Tolerant bacteria can withstand antibiotic killing without having an increase in MIC [44].
To determine whether the mutants were tolerant to the antibiotics, we conducted time-kill
curve experiments and examined their kill kinetics as well as bacterial survival hourly
following antibiotic exposure. Once TIGR4 and the single and double knockout mutants
were actively dividing during the mid-logarithmic phase, they were exposed to lethal
concentrations of a variety of bactericidal antibiotics in different classes. Compared to
TIGR4, the single knockouts ∆sp_1739 and ∆sp_1790 showed reduced killing when
exposed for 4 hours to bactericidal antibiotics, including beta-lactams (cefepime),
glycopeptides (vancomycin), RNA synthesis inhibitors (rifampin), fluoroquinolones
(ciprofloxacin), but not protein synthesis inhibitors (kanamycin) (Figure 5-3). The
double knockout mutant ∆sp_1739∆sp_1790 displayed a similar trend to the single
knockout strain, having less killing to those antibiotics compared to the wild type
(Figure 5-3). Reduced kill kinetics observed in the mutants indicate that the deletion of
the RNA degradation conferred tolerance against several classes of antibiotics.
Furthermore, defects in the RNA degradation machinery caused by multiple mutations
occurring in the mutational hotspot rny likely contributed to the tolerance phenotype that
the experimentally-evolved isolates developed during in vivo passaging.

Deletion of sp_1739 and/or sp_1790 did not significantly attenuate S. pneumoniae
virulence while displaying slight survival advantages in response to antibiotic
treatment
Defects in RNA degradation conferred antibiotic tolerance. We next aimed to
characterize the mutants’ phenotypes both in vitro and in vivo. In the absence of
antibiotics, the ∆sp_1739, ∆sp_1790, and ∆sp_1739∆sp_1790 mutants displayed overall
similar growth rates in vitro (Figure 5-4). We next investigated whether defects in RNA
degradation impart any fitness costs by examining the ∆sp_1739 mutant’s virulence. We
either intranasally or intraperitoneally infected 7-week-old BALB/c mice with TIGR4
316 or the ∆sp_1739 mutant and enumerated bacterial burden in the blood.
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Table 5-3.

MIC of TIGR4 316 and the knockout mutants

Strains
TIGR4 316
∆sp_1739
∆sp_1790
∆sp_1739∆sp_1790

Cefepime
0.032
0.032
0.032
0.032

Antibiotic (µg/mL)
Linezolid
Levofloxacin
3
2
1.5
1.5
3
3
1.5
1.5

Figure 5-3. Disruption in mRNA degradation conferred tolerance to multiple
classes of antibiotics except protein synthesis inhibitors
Time-kill assays were conducted with different antibiotics as indicated at 1x MIC
cefepime, 1x MIC linezolid, 1x MIC ciprofloxacin, 1x MIC vancomycin, 1x MIC
rifampin, and 1x MIC kanamycin. Bacterial number (CFUs/mL) were enumerated 4
hours after antibiotic exposure during exponential phase. Bacterial survival was
calculated as the ratio of CFUs/mL 4 hours post-exposure to the antibiotic to CFUs/mL
pre-exposure.
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Figure 5-4. In vitro growth curves of RNAse Y mutants and TIGR4
The mutants and wild type were grown in the absence of antibiotics, and growth was
recorded by OD every 30 minutes. This experiment was conducted by Juance OrtizMarquez PhD in the Opijnen laboratory at Boston College.
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Due to resource constraints, only the ∆sp_1739 mutant was tested in this
virulence experiment because mutations occurred frequently in sp_1739 during the in
vivo passaging and also is known to be the major endoribonuclease for mRNA decay
[183, 191, 192]. In the low-volume intranasal route of infection, the ∆sp_1739 mutant
was almost fully virulent compared to the wild-type (Figure 5-5). Although there was
approximately 1-log decrease in bacterial burden of ∆sp_1739 mutant in the nasopharynx
(Figure 5-5A), all of the mutants were able to disseminate into the bloodstream as
effectively as the wild type (Figure 5-5B). This suggests that the disruption in RNA
degradation did not attenuate the virulence of S. pneumoniae. A competitive index
between the wild type and the ∆sp_1739 mutant revealed that the mutant outcompeted
the wild type under vancomycin, cefepime, and levofloxacin treatment (Figure 5-6). This
finding was more apparent in the lungs than in the blood (Figure 5-6). These results are
consistent with our previous finding that the experimentally-evolved isolates encoding
many mutations in the rny gene remained virulent while exhibiting antibiotic tolerance.
Taken together, these results suggest that S. pneumoniae likely developed tolerance to
survive under temporary antibiotic pressure without losing bacterial fitness, i.e. virulence
potential.

Discussion
In this study, we aimed to identify mutations(s) and underlying mechanisms of
antibiotic failure in both immunocompetent and immunocompromised hosts. We
demonstrated that antibiotic tolerance developed instead of antibiotic resistance under
antibiotic pressure independent of the host’s immune pressure during our in vivo serial
passaging with the initial set of antibiotics levofloxacin, cefepime, and linezolid
(Figure 5-2). The development of tolerance among the isolates was consistent with
previous studies that showed that cyclic antibiotic treatments promotes tolerance [97,
193-195]. During each round of the in vivo serial passaging, the antibiotics were
administered only once at 7 hours post-infection instead of shorter intervals or continuous
infusion. This presented as transient antibiotic exposure that allows an incomplete
eradication of bacteria population and prolonged bacterial survival under antibiotic
pressure, thus promoting the development of tolerance. After we characterized the
isolates’ tolerance phenotype, we analyzed whole genome sequences of the
experimentally evolved isolates following each round of passaging to identify toleranceassociated mutation(s). Mutations arising during the in vivo serial passaging occurred
most frequently in rny, which encodes the ribonuclease RNAse Y. Deletion mutants of
RNase Y and another essential player of the RNA degradosome complex in S.
pneumoniae also resulted in tolerance and imparted little to no fitness costs (Figure 5-5
and 5-6). Therefore, tolerance was likely attributed to the resultant defects in RNA
degradation. The rny knockout mutant exhibited tolerance to a variety classes of
antibiotics, except the protein synthesis inhibitors, such as kanamycin (Figure 5-3).
Defects in RNA degradation increased intracellular RNA concentration, which likely
upregulates the downstream protein synthesis to decrease the RNA levels and make
nucleotides available for other cellular processes.
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Figure 5-5. Disruption RNA degradation decreased S. pneumoniae virulence in
the nose but not in the blood
Seven-week-old mice were intranasally infected, and nasal and blood samples were
harvested 24 hours post-infection A) Nasal titers. B) Blood titers. *p-value ⩽ 0.05.
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Figure 5-6. ∆sp_1739 mutant showed increased survival under vancomycin,
cefepime, and levofloxacin treatment during competitive index (CI) experiment
Mice were infected intranasally with high-volume inoculum containing equally mixed
TIGR4 and ∆sp_1739. Sixteen-hour post-infection, infected mice were then peritoneally
administered levofloxacin, cefepime, or vancomycin at dosages that eliminated
approximately 90% of the bacteria. Blood and lungs were harvested via dissection, and
bacteria were collected via centrifugation and serially tittered. Competitive index of the
∆sp_1739 and the wild type was calculated as the ratio of the CFUs/mL of the mutant to
that of TIGR4.
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Tolerance might have been the bacterial survival strategy withstanding the
transient exposure to the antibiotic while minimizing fitness costs of defects induced by
on-target mutations. In stress conditions, it would be beneficial for bacteria to maintain
only specific sets of mRNA to focus on translation of genes essential for overcoming that
particular stressor, therefore mRNA degradation would be essential for the rapid adaption
to environmental changes in order to shift responses specific for that stressor. Thus, a
critical role of mRNA degradation is replenishing ribonucleotides for synthesis of
essential transcripts specific for that particular stressor.
Tolerance induced by disruption of RNAse Y and/or RNA helicase facilitated the
acquisition of antibiotic resistance via de novo mutations. Tolerance prolongs bacterial
survival, potentially enabling replication after completion of antibiotic treatment. With
higher numbers of bacterial survival during antibiotic exposure, more mutations that
occur during subsequent replication may be deemed favorable and select for antibiotic
resistance. However, no increase in transformation efficiency was observed with
fluoroquinolones. Although, we have not tested transformation efficiency of the
experimentally-evolved isolates with other antibiotics, we hypothesized that fitness costs
might have been increased due to simultaneous disruption of RNA degradation and DNA
replication. DNA replication is likely inhibited by accumulated RNA through negative
feedback mechanisms. Fluoroquinolone resistance mutations in gyrA and parC have been
shown to interrupt DNA replication [196], therefore compounding the inhibition of DNA
replication previously due to disrupted RNA degradation. As part of our ongoing and
future research, we plan to generate point mutants in the rny gene to characterize their
individual contributions to the isolates’ tolerance phenotype. The most frequently
occurring mutations will be selected to generate the point mutants as they show the
greatest potential to confer tolerance and minimize fitness costs. Different combinations
of those mutations will also be generated because some may act as compensatory
mutations restoring bacterial fitness, rather than conferring tolerance.
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CHAPTER 6. VANCOMYCIN HETERORESISTANCE AND CLINICAL
OUTCOMES IN COAGULASE-NEGATIVE STAPHYLOCOCCAL
BLOODSTREAM INFECTIONS1

Introduction
Vancomycin is the definitive therapy for many serious gram-positive infections;
however, although most such infections remain susceptible to vancomycin, therapeutic
failure is common. One potential explanation for the poor outcomes is heteroresistance,
that is, the presence of a small subpopulation of resistant organisms recalcitrant to
antibiotic therapy. This phenomenon has been well-described in some bacteria, including
Enterobacteriaceae and Staphylococcus aureus [46, 198].
Heteroresistance does appear to be associated with poor treatment outcomes in
methicillin-resistant S. aureus infections [51, 198]; however, the clinical significance of
heteroresistance in coagulase-negative staphylococci (CoNS) is unknown [199-205].
CoNS are gram-positive bacteria that colonize human skin and mucosa. They are a
frequent etiology of central line–associated bloodstream infections (CLABSI), especially
in immunocompromised patients [206-208]. Although often thought of as benign, CoNS
CLABSI in vulnerable populations can cause prolonged hospitalization and serious
illness, including organ dysfunction and neurocognitive damage [209, 210]. These
bacteria typically appear susceptible to vancomycin, which is recommended as first-line
therapy; however, antibiotic treatment failure or relapse is common [211, 212].
The possibility that heteroresistance contributes to poor clinical response in CoNS
infections has not been evaluated. Clinical susceptibility testing, which uses an inoculum
of approximately 106 CFU/mL, typically cannot detect a resistant subpopulation at a
frequency of 10−6 or lower. Since the genetic basis for vancomycin heteroresistance
remains unknown, molecular testing is unavailable. Therefore, vancomycin
heteroresistance might be present in CoNS causing bloodstream infections in
immunocompromised patients and might impair the clinical response to vancomycin
therapy. We undertook a retrospective study to evaluate the frequency, risk factors, and
clinical significance of vancomycin heteroresistance in CoNS CLABSI in pediatric
patients undergoing treatment for leukemia at St. Jude Children’s Research Hospital (St.
Jude).

1

Reprinted from final submission with permission. Tina H. Dao, Ramzi Alsallaq, Joshua
B. Parsons, Jose Ferrolino, Randall T. Hayden, Jeffrey E. Rubnitz, Iftekhar M.
Rafiqullah, D. Ashley Robinson, Elisa B. Margolis, Jason W. Rosch, Joshua Wolf.
Antimicrobial Agents and Chemotherapy. Oct 2020, 64 (11) e00944-20;
http://doi.org/10.1128/AAC.00944-20 [197].
197.

Infections Caused by Coagulase-Negative Staphylococci. Antimicrob Agents Chemother, 2020. 64(11).
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Methods

Clinical data
This was a retrospective cohort study comprising all patients who developed
CoNS CLABSI during treatment for leukemia at St. Jude between January 1, 2010, and
March 28, 2016. The study was approved by the St. Jude institutional review board
(approval XPD16-036). Participants were identified from the electronic medical record,
and data on demographics, malignancy, vancomycin exposure, and infection outcomes
were abstracted from the electronic medical record. Episodes were excluded if the isolate
was not available for testing, was not identified as CoNS on sequencing, or was not
successfully tested for heteroresistance.

Bacterial isolates
CoNS isolates were obtained from the clinical microbiology laboratory, where
they were stored for quality assurance purposes in glycerol at −80°C until tested. A
prototypical vancomycin-heteroresistant S. aureus strain (Mu3) was obtained from ATCC
(Manassas, VA) for use as a positive control. All isolates were classified as susceptible to
vancomycin by conventional testing (with VITEK 2.]; MIC range, <0.5–2 µg/mL) [213].

Evaluation of vancomycin heteroresistance
Population analysis profiling (PAP) was used to identify vancomycin
heteroresistance in clinical isolates. PAP was performed in accordance with standard
published techniques for detecting hetero–vancomycin-intermediate S. aureus (hVISA)
[50, 214]. Each isolate was grown in 10 mL of tryptic soy broth (BD Sciences, catalog
no. 211825) overnight at 37°C. Of the 74 available clinical isolates, 30 were analyzed in
2016 and 44 were analyzed in 2017. The latter set of isolates required the addition of
0.2% yeast extract (BD Biosciences, catalog no. 212750) for growth. Overnight
stationary-phase cultures were serially diluted 1:100 in 1× PBS to give dilutions ranging
from 10−2 to 10−8, and 100 μL of each dilution was spread on brain heart infusion (BHI)
agar plates (made from Bacto Brain Heart Infusion and Bacto agar from BD Biosciences)
containing 0, 1, 2, 4, 6, or 8 μg/mL of vancomycin (vancomycin hydrochloride, SigmaAldrich, St. Louis, MO). Each strain at each dilution was inoculated onto duplicate plates
for each antibiotic concentration. After a 48-h incubation at 37°C, colonies were
enumerated to estimate the bacterial survival, expressed as colony-forming units per
milliliter (CFU/mL), at each vancomycin concentration. The average number of colonies
on duplicate plates was used to calculate the CFU/mL for each vancomycin
concentration; CFU/mL was plotted as a function of vancomycin concentration, and the
area under the curve (AUC) was calculated using GraphPad Prism 7. The AUC for each
clinical isolate was then compared by a simple ratio to the average AUC for the
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heteroresistant reference strain Mu3, obtained using the identical technique, and if the
AUC ratio was 0.9 or greater, the isolate was classified as heteroresistant [50].

Genomic sequencing
Each clinical isolate was inoculated in TSB and grown overnight at 37oC for
DNA extraction. The entire overnight culture of each isolate was pelleted at 6000 RPM
for 10 min, and the pellets were resuspended in TSM solution (50 mM Tris, pH 7.5, 0.5
M sucrose, 10 mM MgCl2) before the addition of lysostaphin at 2 mg/mL. The mixture
was then incubated at 37°C for 10 min. Once the bacterial cells had lysed, DNA was
extracted using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI) in
accordance with the manufacturer’s instructions. DNA libraries for next-generation
sequencing were prepared using a Nextera DNA Flex Library Kit (Illumina, San Diego,
CA) and sequenced on an Illumina Hi-Seq 2000 sequencing system.

Sequencing and typing
Sequence reads for 74 clinical strains and Mu3 were adapter trimmed (minimum
length 15 bp) and then quality trimmed (minimum base quality 12) by using BBMap
(https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/). Sequences
were assembled de novo by using SPAdes v3.11.1. Sequence types (STs) from speciesspecific multilocus sequence typing (MLST) schemes were extracted from the assemblies
by using mlst v2.8 (https://github.com/tseemann/mlst). For Staphylococcus epidermidis
strains with typeable STs, genetic clusters were assigned according to the method of Tolo
et al.[215]. Sequences were aligned by the Burrows–Wheeler Alignment tool bwa
v0.7.17, using S. epidermidis DAR1907 (GenBank accession no. CP013943.1) as a
reference strain. Sequences were coordinate sorted by using Picard v1.141 and realigned
around short insertion–deletion polymorphisms (indels) with Genome Analysis Toolkit
(GATK) v2.8-1. Variants were called by GATK and filtered for a minimum base quality
of 30 and the presence of the variant in all strains. The functional effects of the variants
were determined using SnpEff v4.

Statistical analysis
The first available episode for each participant was used to evaluate associations
between preceding vancomycin exposure and heteroresistance. Preceding vancomycin
exposure was calculated as the number of days in the preceding 60 days on which
intravenous vancomycin was administered. The Mann–Whitney U test was used to
evaluate the significance of differences between groups. An unadjusted P-value of less
than 0.05 was considered to indicate statistical significance.
To evaluate associations between heteroresistance and clinical outcomes, the first
episode for each participant was again selected, but episodes that were probably the result
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of contaminants, defined as episodes with single positive blood cultures and at least 1
simultaneously collected negative blood culture, were excluded. Treatment failure was
defined as death during the CLABSI episode or recurrence of BSI with the same
organism within 180 days; poor clinical response was defined as persistent positive blood
cultures collected at least 1 day after the initiation of vancomycin or treatment failure as
defined above. Poor clinical response was designed to be a more sensitive measure of
decreased initial response to vancomycin therapy, as death and recurrence are relatively
uncommon in this cohort.
The log-rank test was used to compare the cumulative incidence of each clinical
outcome with heteroresistant and non-heteroresistant bacteria. Cases were censored at
unrelated death, completion of cancer therapy, permanent discharge from the institution,
180 days after onset of BSI, or completion of the study period. Potential confounders
were each evaluated for their association with outcome and were included in stratified
survival analyses, pooled over all strata, if the P value was 0.1 or less. Statistical analyses
were performed with SPSS (IBM SPSS Statistics for Windows, Version 26.0: IBM
Corporation, Armonk, NY)

Results

Incidence of heteroresistance
A total of 74 isolates from 65 study participants were available; 7 participants had
2 episodes of CoNS CLABSI and 1 had 3 episodes. Two of the 65 participants were
excluded because their isolates were not identified as CoNS following sequencing, and 1
was excluded because the heteroresistance testing was unsuccessful due to poor in vitro
growth. The characteristics of the 62 included participants are presented in Table 6-1.
Analysis of the first isolates from all participants revealed that 24 (39%) were classified
as heteroresistant, suggesting that heteroresistance is common in CoNS isolated from
bloodstream infections in the pediatric leukemia population.

Genetic characterization of bacterial isolates
Most isolates were identified as S. epidermidis by sequencing (Table 6-2). All
heteroresistant isolates were S. epidermidis (P = 0.005), but they represented several
sequence types. The most common sequence type was ST2, a well-known hospital
pathogen [216], and all S. epidermidis isolates were classified as members of genetic
clusters associated with hospital sources (GC1, GC5, and GC6) [215, 217]. There was no
evidence of clonal outbreaks, but all heteroresistant isolates were S. epidermidis, with no
heteroresistance being observed in either S. haemolyticus or S. hominus.
We next looked for mutations in genes known to confer vancomycin resistance.
Mutations in rpoB, specifically D471E and I527M, are associated with resistance to

94

Table 6-1.

Characteristics of evaluable participants (n = 62)

Characteristic
Age in years,
mean (SD)
Sex
Female
Male
CVC type
Tunneled
CVC
Port
PICC
Other
Leukemia type
ALL
AML
History of
HCT
Race
White
Black
Other

Non-heteroresistant
(n = 38)
n
(%)
10.6
(6.2)

Heteroresistant
(n = 24)
n
(%)
7.5
(6.3)

All participants
(n = 62)
n
(%)
9.4
(6.4)

12
26

(31.6%)
(68.4%)

14
10

(58.3%)
(41.7%)

26
36

(41.9%)
(58.1%)

14

(36.8%)

16

(66.7%)

30

(48.4%)

15
2
7

(39.5%)
(5.3%)
(18.4%)

4
0
4

(16.7%)
(0%)
(16.7%)

19
2
11

(30.6%)
(3.2%)
(17.7%)

26
12
7

(68.4%)
(31.6%)
(18.4%)

13
11
6

(54.2%)
(45.8%)
(25%)

39
23
13

(62.9%)
(37.1%)
(21%)

28
7
3

(73.7%)
(18.4%)
(7.9%)

16
4
4

(66.7%)
(16.7%)
(16.7%)

44
11
7

(71%)
(17.7%)
(11.3%)

SD, standard deviation; CVC, central venous catheter; PICC, peripherally inserted central
catheter; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HCT,
hematopoietic cell transplantation
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Table 6-2.
Species and multilocus sequence type for all first included CoNS
isolates (n = 62)

Species/Sequence Type
Staphylococcus epidermidis
ST2
ST5
ST16
ST22
ST23
ST57
ST73
ST83
ST89
ST173
ST218
ST291
NT
Staphylococcus haemolyticus
ST1
ST3
NT
Staphylococcus hominis
ST18
NT
Total

Non-heteroresistant
(n = 38)
n
(%)
28
53.8
7
58.3
3
33.3
2
100
0
0
0
0
0
0
0
0
3
60
1
100
0
0
1
50
0
0
11
73.3
4
100
1
100
1
100
2
100
6
100
2
100
4
100
38
(61.3%)

Heteroresistant
(n = 24)
n
(%)
24
46.2
5
41.7
6
66.7
0
0
1
100
1
100
1
100
1
100
2
40
0
0
1
100
1
50
1
100
4
26.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
(38.7%)

ST, sequence type; %, percentage of species/sequence type; NT, non-typeable
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rifampicin and vancomycin in strains of S. epidermidis of ST2 and ST23 lineages [216].
Mutations in rpoB were identified in 8 S. epidermidis strains, of which 3 were
heteroresistant. One strain of ST23 had dual resistance alleles in rpoB (E471, M527); it
was resistant to rifampicin (MIC > 32) and heteroresistant to vancomycin. This suggests
that mutations in rpoB are neither necessary nor sufficient for vancomycin heteroresistance in the studied strains.

Vancomycin exposure
We next tested whether vancomycin exposure before infection increased the risk
of a heteroresistant organism being recovered. In the 60 days before infection,
participants with heteroresistant CoNS had received more days of vancomycin therapy
(P = 0.11) and more days of vancomycin prophylaxis (P = 0.026) than had participants
without heteroresistant CoNS (Figure 6-1). These data suggest that prolonged exposure
to intravenous vancomycin at the subtherapeutic doses used for prophylaxis may
contribute to the emergence or selection of heteroresistant bacterial populations.

Effect of heteroresistance on clinical outcomes
We evaluated the effect of vancomycin heteroresistance on the clinical response
to vancomycin treatment. Only 40 episodes were included in this analysis; the other 22
were excluded as being possibly attributable to blood culture contamination (see
exclusion criteria in methods). Seven of these 40 participants (18%) experienced
treatment failure and 15 (38%) experienced poor clinical response. Of 6 participants with
relapse of infection, sequence typing was available for 3 pairs of isolates; in all cases, the
sequence type of the initial and subsequent isolates were identical. Participants with
heteroresistant infections had higher cumulative incidences of treatment failure
(P = 0.012) (Figure 6-2) and poor clinical response (P = 0.001) (Figure 6-3) when
compared to participants without heteroresistant infections. Of the other variables
evaluated, only vancomycin MIC and age of the participant were considered to be
potential confounders. Vancomycin MIC was significantly associated with poor clinical
response (P = 0.037) but not with treatment failure (P = 0.669). Age group was also
significantly associated with poor clinical response (P = 0.023), but its apparent
association with treatment failure was not statistically significant (P = 0.054). Variables
that were not associated with treatment failure or poor clinical response were CVC type
(P = 0.727 and P = 0.377, respectively), leukemia type (P = 0.476 and P = 0.939,
respectively), sex (P = 0.800 and P = 0.601, respectively), and self-reported race
(P = 0.802 and P = 0.964, respectively). Therefore, vancomycin MIC and participant age
were included in stratified analyses. These analyses showed that poor clinical response
and treatment failure remained associated with heteroresistance after controlling for
vancomycin MIC (P = 0.008 and P = 0.021, respectively) and for age group (P = 0.014
and P =0 .12, respectively). An additional subgroup analysis restricted to S. epidermidis
isolates also showed that heteroresistance was significantly associated with treatment
failure (P = 0.028) and poor clinical response (P = 0.006).
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Figure 6-1. Vancomycin exposure in the 60 days before infection for
heteroresistant and non-heteroresistant isolates (N = 62)
Box plots showing the differences between heteroresistant and non-heteroresistant
infections with respect to vancomycin exposure (P = 0.11) and prophylactic vancomycin
exposure (P = 0.026). The boxes represent the 25th to 75th percentiles, the whiskers
extend up to 1.5 times the box height, and the circles and stars represent outliers and
extreme outliers, respectively.
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Figure 6-2. Cumulative incidence of treatment failure in patients with CoNS
bloodstream infection (N = 40)

Figure 6-3. Cumulative incidence of poor clinical response in patients with CoNS
bloodstream infection (N = 40)
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Discussion
In this study, vancomycin heteroresistance was common in CoNS isolates from
CLABSIs in children with leukemia. Data on the incidence of heteroresistance in CoNS
are limited, but the high rate found in this study is similar to that reported for various
CoNS species in various disease contexts in previous studies [199-205, 218]. Clonal
spread of heteroresistant CoNS has been described previously, especially in neonatal
intensive care units [204, 219]. However, in this study, there was no single genetic
marker for heteroresistance and a wide range of sequence types was involved. This
suggests that the phenomenon of heteroresistance likely emerged on multiple occasions
and by different mechanisms. Gene amplification may be a key genetic mechanism of
heteroresistance in gram-negative bacteria [220]. However, heteroresistance to
vancomycin may differ from heteroresistance to other antibiotics; because gram-positive
organisms commonly have high MICs within the susceptible range (the result of “MIC
creep”) [221], heteroresistance might emerge from minor changes in these near-resistant
subpopulations, rather than from the dramatic increases in MIC seen in gram-negative
species.The study has some important limitations. The retrospective nature of the data
collection means that some information might have been missed or misclassified or some
confounding variables excluded. Additional variables, such as CVC-removal and
concomitant antibiotic therapy, were not included in the analysis, but were not expected
to vary by heteroresistance status. The finding of poorer clinical outcomes in patients
with heteroresistant infections might also be attributed to host factors, linkage
disequilibrium, or another factor that affects heteroresistance testing. Because the method
of detecting heteroresistance is not standardized, alternative laboratory approaches might
yield different results and interpretations. Using a sensitive but non-standard definition of
poor clinical response improved our ability to evaluate the effect of heteroresistance on
clinical outcomes, but the clinical relevance of these outcomes is uncertain. A major
challenge to incorporating heteroresistance measurement into clinical practice and
diagnosis is the absence of a widely accepted clinical test for the heteroresistance
phenotype. In cases of infection for which rapid diagnosis and susceptibility testing are
paramount, the time- and resource-intensive methodology used in this study is likely to
be impractical.
The study also has several strengths that support our findings. We were able to
connect information obtained from laboratory experiments to clinical data for a large
cohort of patients with CoNS bloodstream infection, which enabled us to demonstrate the
differences in clinical outcomes associated with heteroresistance. The 180-day duration
of follow-up was appropriate because relapse of CLABSI after that time is uncommon
[222, 223]. Including isolates collected during the same time period and from the same
population helped to exclude confounding by secular or cohort effects.
Similar to other mechanisms of resistance, prior exposure to antibiotics increased
the risk of heteroresistance for this study population [224, 225]. Intriguingly, exposure to
intravenous vancomycin administered as prophylaxis appeared to be more strongly
associated with risk of heteroresistance than were other intravenous exposures.
Subtherapeutic antibiotic levels over an extended period may provide strong selective
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pressure by encouraging the emergence of heteroresistance or helping to maintain
transient heteroresistance that emerges as a result of unstable gene amplifications or
mutations [226]. The immunocompromised state of the study participants might also have
contributed to the evolution of heteroresistance by reducing the rate of clearance of
heteroresistant bacteria [227]. Concerns about contributing to the rise of antibiotic
resistance have limited the implementation of glycopeptide prophylaxis [228, 229]. A
previous study found that vancomycin prophylaxis increased the risk of vancomycinresistant enterococcal (VRE) infections [229]; therefore, the finding that vancomycin
prophylaxis also appears to contribute to heteroresistance in CoNS is important.
Modeling of heteroresistance in mammalian models has suggested that it can
contribute to antibiotic treatment failure in patients with S. aureus, Enterobacter spp., or
Klebsiella spp. infections [51, 52, 230]. Moreover, vancomycin heteroresistance in S.
aureus infections appeared to contribute to treatment failure in multiple studies [231,
232]. However, little information is available about the effect of heteroresistance on
outcomes in CoNS infections. One case-control study including CoNS and S. aureus
found increased mortality in patients with heteroresistant infections [205], and a recent
case report described a neonate with a heteroresistant Staphylococcus capitis infection
that responded poorly to treatment with vancomycin [233]. To our knowledge, this cohort
study is the first to show that the clinical response to vancomycin is demonstrably worse
in infections caused by heteroresistant CoNS.
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CHAPTER 7.

CONCLUSION

In conclusion, as we have seen in chapters 2, 3 and 4, fitness tradeoffs present a
major barrier to the acquisition of fluoroquinolone and beta-lactam resistance via
horizontal transfer in S. pneumoniae. To fight against antibiotics, the bacteria must
maximize resistance potential without compromising their fitness.
In chapter 2, S. pneumoniae does not readily acquire on-target fluoroquinolone
resistance determinants from resistant pneumococcal and viridans clinical isolates via
horizontal transfer. The low prevalence of fluoroquinolone resistance is likely partly
attributed to high fitness costs associated with on-target mutations in gyrA and parC.
Another possible contributing factor is that high-level resistance to fluoroquinolones
require the contribution of multiple on-target mutations, which could be simultaneously
acquired via horizontal transfer. In chapter 3, a potential off-target mutation N291D in
the patA efflux could potentially facilitate the acquisition of subsequent high-level
fluoroquinolone resistance.
In chapter 4, similar to fluoroquinolone resistance, horizontal transfer can
facilitate the development beta-lactams resistance, but with a cost. Early recombinants
may retain virulence in vivo and achieve similar levels of β-lactam resistance with
experimentally evolved penicillin-resistant populations. Recombination with related
species may be preferable in S. pneumoniae to develop tolerance and more rapidly
achieve subsequent resistance without initially sacrificing in vivo fitness.
In chapter 5, in S. pneumoniae, disruptions in RNA degradation also resulted in
antibiotic tolerance that likely reduces antibiotic efficacy. Tolerance is likely a strategy
for S. pneumoniae to withstand antibiotic killing while minimizing fitness tradeoffs and
preparing for the subsequent acquisition of resistance. And in chapter 6, we found that
heteroresistance in CoNS is associated with poor clinical outcomes and treatment failure
in pediatric patients with leukemia at St. Jude Children’s Research.
The findings of this dissertation will provide insights into the underlying
mechanisms that facilitate the acquisition of high-level antibiotic resistance and reduce
antibiotic efficacy. Understanding those mechanisms will be critical for the development
of more-effective antibiotics and surveillance.
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